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Aqueous Two-Phase Systems for Next-Generation Biotechnological Assays 
by 
Joshua B. White 
 
Next-generation biotechnological assays, described here as those that increase 
throughput, improve upon physiological relevance, accomplish previously impossible biological 
and/or engineering tasks, or some combination thereof, will play increasingly crucial roles in the 
healthcare, biotechnology, and pharmaceutical industries in the next several decades. 
Unfortunately, although many of the recent technological innovations that have been achieved 
accomplish these goals, they are also commonly burdensome, technologically challenging, and 
perform highly niche tasks, thereby making them difficult and sometimes impossible to adopt 
into the healthcare, biotechnology, and pharmaceutical industries that would benefit most from 
them. This dissertation has four chapters, each of which describes the application of an aqueous 
two-phase system (ATPS) for next-generation biotechnological assays. The importance and 
relevance of these assays is discussed in the context of drug development in the pharmaceutical 
industry, where there has been decreasing return-on-investment despite the influx of billions of 
dollars in research and development. First, ATPS-immunocytochemistry was used to stain for 
multiple biomarkers from a single cell monolayer and do so more rapidly and with higher signal 
intensity than traditional cell staining. An ATPS of 5% polyethylene glycol (PEG) and 12.8% 
dextran (DEX) was then determined to be the optimal system with which to perform cell 
monoculture patterning for high-throughput screening analysis of cell migration and to perform 
co-culture patterning to achieve more physiologically relevant cell behavior that can be used as a 
toxicological and/or functional screening assay. ATPS was further used to create an assay that 
localizes trypsin to achieve reproducible and high-throughput in vitro wounding on transwell 
inserts. Finally, an ATPS-enzyme-linked immunosorbent assay (ELISA) was developed to 
pattern detection antibodies and quantify 4 biomarkers of graft-versus-host-disease without 
antibody cross-reactivity and with greater sensitivity compared to traditional ELISA. Such next-
generation technologies will provide a launching point for the development of user-friendly, 
easily adoptable, and scalable assays that can be utilized by both basic science researchers and 
for-profit biotechnology industries to better characterize diseases and develop therapeutics.  




Introduction and Thesis Overview 
1.1 Drug Discovery and the Pharmaceutical Industry 
Since the 1990s, a decade when pharmaceutical companies experienced incredible 
success in the development of blockbuster drugs that translated into billions of dollars of 
revenue, there has been a significant decline in the creation of breakthrough medicines despite 
increasing investments in pharmaceutical research and development (R&D) (Munos, 2009). In 
fact, it was estimated that there was a 50% reduction in the approval of new molecular entities by 
the FDA and other regulatory bodies from 2005-2010 compared to 2000-2005 (Mathieu, 2008). 
This decline in productivity can be thought of in terms of reduced efficiency, the decline in the 
number of drugs produced from a library of potential compounds, and reduced effectiveness, the 
inability to translate drug candidates into revenue-producing pharmaceuticals (Paul et al., 2010). 
A recent industry-wide analysis outlined several factors that have contributed to this decline: lags 
between the introduction of technological innovations and the ability to translate those 
innovations into successful drugs, the pursuit of projects with lower probabilities of success, and 
increased attrition rates in clinical trials (Pammolli et al., 2011).  
Biotechnological innovations like mapping the human genome and microbiome, 
epigenetics, and stem cell therapy have shown promise in the development of targeted and/or 
personalized medications. Although these breakthroughs have attracted interest for their potential 
to help understand and treat molecular mechanisms of disease on a personal level, they have yet 
to be successfully translated into therapies on a large scale. The disconnect between these 
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technologies’ promise and their apparent lack of efficacy are likely due to the fact that they were 
discovered in the last 10-20 years and are still not fully understood. The human genome project, 
for example, was started in 1990 (Human Genome Project Information) and has provided 
incredible amounts of information regarding gene expression, regulation, and dysregulation. 
However, through this research, it has become apparent that the molecular mechanisms 
regulating various diseases are often very complex and cannot be traced to a single specific 
genetic abnormality. Even cystic fibrosis, a disease often caused by a single mutation in the 
cystic fibrosis transmembrane conductance regulator (CFTR) protein, has several different 
subtypes that result in different phenotypic outputs (O’Sullivan and Freedman, 2009). Although 
mutation-specific treatments are available, they generally only alleviate symptoms instead of 
curing the underlying problem. With diseases that are more complicated, such as cancer, it 
becomes apparent that treatment of these disorders with multiple underlying mutations and 
complex regulatory networks will require a better understanding of the biomolecular pathways 
that regulate these diseases and the development of multi-faceted approaches for treating these 
disorders. 
The pursuit of projects with low probabilities of success is due to a combination of 
technical and market-based challenges. For example, it has been hypothesized that many of the 
easily-targeted diseases already have drugs to treat them and the remaining diseases without 
therapeutics are mechanistically more complex and difficult to treat (Scannell et al., 2012). 
Furthermore, changes in the way targets are selected may also contribute to the decline in drug 
development efficiency. Early screening approaches relied more on phenotypic screens that “cast 
a wide net” for potential therapeutic targets (Swinney and Anthony, 2011) as well as iterative 
screening that made small modifications to potential compounds in a stepwise manner to slowly 
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but surely approach a robust final product. Conversely, current drug development often uses 
genomics and proteomics to find a specific treatable target, and in doing so, may decrease the 
likelihood of finding a compound with which to treat it. Furthermore, high-throughput screening 
approaches that simultaneously analyze thousands of compounds for potency often disregard 
other critical factors such as drug absorption, bodily distribution, metabolism, and excretion 
(Scannell et al., 2012). In doing so, researchers are prone to missing potentially efficacious 
compounds while also including potent drugs that possess negative pharmacokinetic behavior 
that could limit a compound’s potential for success in later trials. Not only do technical 
challenges plague the drug discovery process, but market-based forces have also led to a decline 
in productivity. There has been a shift in pharmaceutical R&D spending toward high risk and 
high potential reward compounds such as those to treat cancer, Alzheimer’s, obesity, and 
rheumatoid arthritis (Pammolli et al., 2011). Although the likelihood of creating compounds to 
treat these complex diseases is low, there is also the potential for a significantly higher return on 
investment due to a higher likelihood for medical reimbursement from insurance companies, 
fewer competitors in the landscape, and patent protection. Therefore, improving the likelihood of 
success in drug development will require companies to not only develop more effective technical 
approaches but also strategic business plans to optimize the return on investment. 
Finally, the most costly and crippling aspect of drug development, the failure of drugs in 
clinical trials, is partially a byproduct of the challenges mentioned above regarding new 
technology and selecting the appropriate targets and compounds. By selecting inefficacious 
compounds or high risk drug profiles, there is inherently a higher likelihood of failing at later 
stages in the drug development process. This is reflected in the startlingly high clinical attrition 
rates in both Phase II and Phase III; from 2008-2010, 51% of Phase II compounds failed due to 
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lack of efficacy and another 19% failed due to safety concerns, similarly, from 2007-2010, 66% 
and 21% of Phase III compounds failed due to lack of efficacy and safety, respectively (Khanna 
2012). Improvements in early-stage discovery processes could increase the likelihood for success 
during clinical trials; these improvements might come from comprehensive biostatistical analysis 
and epidemiological studies of patient populations, computational models, and novel screening 
and diagnostic technologies. Unfortunately, with regards to new and/or enabling technologies, 
many of the technologies that are developed in academic settings are overly-complicated, require 
highly specialized instrumentation and workers, and are not scalable, thereby making them 
difficult or impossible to implement on a large scale. Therefore, next-generation technology will 
not only need to be able to better predict compound efficacy, but it will also need to seamlessly 
interface with existing infrastructure. In this regard, aqueous two-phase systems (ATPSs) may 
provide an easily scalable and adoptable approach with which to create more physiologically 
relevant in vitro assays and high-throughput screening for early-stage drug development, pre-
clinical compound testing, and testing at the clinical stage of development. 
  
1.2 Aqueous Two-Phase Systems 
An ATPS forms when two aqueous solutions that are enriched with different polymers or 
a polymer and a salt are mixed at sufficiently high concentrations. The solubilized polymers and 
salts cause the solutions to become incompatible, and as a result, the individual aqueous phases 
remain immiscible. This phenomenon was first recognized in 1896 by Martinus Beijerinck, who 
discovered that aqueous solutions of agar were immiscible with other aqueous solutions of starch 
or gelatin (Beijerinck, 1896). Since this initial discovery, the investigation of ATPSs has become 
a field of study unto itself and researchers have even extended the application to multiphase 
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systems with upwards of 18 distinct phases (Albertsson, 1960). Although enthalpic and entropic 
theoretical considerations have been used to predict and/or explain the formation of ATPSs 
based on Flory-Huggins theory for polymer solutions (Baskir et al., 1989a; Baskir et al., 1989b; 
Sjöberg and Karlström, 1989), oftentimes an empirical approach is required to determine if an 
ATPS will form based on the following parameters: polymer molecular weights, salt 
concentration, temperature, and solution pH. The resulting output of these experiments is a 
binodal curve, which delineates the concentrations of each polymer and/or salt in solution that 
lead to the formation of a single or two-phase system.  
Once a two-phase system has been characterized, it can be utilized for various interesting 
applications. One area that has been heavily investigated is the use of ATPSs in separation and 
purification techniques in industrial-scale biological processes (Asenjo and Andrews, 2011). 
Two characteristics of ATPSs make them especially useful for purifying and/or extracting 
specific biomolecules from solution: low interfacial tension and biomolecule partitioning. First, 
unlike oil/water systems that have high surface tensions that lead to the denaturation of proteins 
and other biomolecules, ATPSs have low surface tensions and are highly biocompatible, thereby 
preserving the structure and function of active biological material. Second, passive partitioning 
of certain biomolecules can generate highly purified and/or concentrated solutions. Furthermore, 
partitioning behavior is dependent, to a degree, on the physicochemical properties of the ATPS. 
Therefore, by altering the hydrophobicity, concentrations, and molecular weights of polymers in 
the ATPS, as well as pH and concentrations of various salts in solution, one can modify partition 
behavior (Albertsson, 1986). This is especially useful for protein purification due to the diverse 
range of protein conformations, charges, sizes, and hydrophobicities. For example, Tubío et al. 
used different concentrations and molecular weights of polyethylene glycol (PEG) and sodium 
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citrate, as well as salt enrichment with NaCl, to enhance trypsin and α-chymotrypsin localization 
to the citrate phase of the ATPS (Tubío et al., 2007). 
Although ATPSs have been effectively utilized for biomolecule purification, our lab has 
continued to investigate their use for biotechnological applications. Using an ATPS of PEG and 
dextran (DEX), it was demonstrated that lipofectamine and lentiviruses could be partitioned to 
the DEX phase; using the ATPS, these transfection reagents were then patterned over a 
monolayer of cells in an array format to promote the expression of fluorescent proteins (Tavana 
et al., 2009). Since this initial work was performed, numerous other applications and methods 
have been developed to take advantage of the ability to easily and discretely pattern biomaterials 
and cells. Cell patterning of individual or multiple cell types using PEG/DEX ATPSs has been 
accomplished in a variety of formats including pipetting (Tavana et al., 2010; Tavana et al., 
2011, Frampton et al., 2013b), acoustics (Fang et al., 2012), and microfluidics (Frampton et al., 
2011). It was also demonstrated that PEG/DEX ATPSs could be combined with microbubble 
technology to localize sonoporation of cells (Frampton et al., 2013a) and with picoliter 
dispensing systems to achieve single cell or subcellular delivery of proteases and other 
biomolecules (Frampton et al., 2013c). 
ATPS-based assays, therefore, may be especially useful and interesting in biotechnology 
and potentially drug discovery and development for several reasons. First, the core technology is 
extremely easy to implement and therefore more amenable to adoption in biology-based labs and 
other research settings that are averse to adopting new and complex technology (Berthier et al., 
2012). Second, ATPSs can create more physiologically relevant in vitro settings that may be 
better able to predict cellular or organ-level responses and therefore be a better early indicator of 
drug success (Neužil et al., 2012). Finally, the ability to pattern small arrays of cells and/or 
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biomolecules enables high throughput screening that can generate more reliable data. These 
types of next-generation assays will be crucial to enable researchers and clinicians to develop 
more efficacious treatments and thereby curb the rising costs associated with drug development 
and health care. 
 
1.3 Dissertation Overview 
This work is divided into four separate chapters, each describing a way in which ATPSs are 
applied to pattern cells and/or biomolecules and can be utilized to improve the drug development 
process. Chapter 2 describes the application of ATPS-based localization of antibodies for high 
throughput and multiplexed biomarker detection from cell monolayers. Chapter 3 describes 
single cell and co-culture cell patterning and provides examples of several basic functional 
readouts that can be performed. Chapter 4 demonstrates a method by which an ATPS can be 
utilized to locally deliver trypsin to generate an in vitro wound on transwell inserts. Chapter 5 
discusses the application of an ATPS to localize antibodies in an enzyme-linked immunosorbent 
assay (ELISA) for crosstalk-free and multiplexed detection of patient proteins as a way to better 
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Aqueous Two-Phase Localized Immunocytochemistry for 
Multiplexed Protein Detection 
This chapter describes the use of a PEG/DEX ATPS for localizing antibodies on a monolayer of 
cells. Antibody partitioning was first demonstrated by equilibrating an antibody-enriched ATPS 
and then reading signals produced from aliquots of each phase by dot blot. After demonstrating 
antibody partitioning, staining characteristics of the system were characterized based on polymer 
concentrations of the ATPS, droplet volumes of the dispensed DEX, and incubation times. The 
versatility of the technique was highlighted by using ATPS to localize primary and/or secondary 
antibodies, as well as by producing signals in colorimetric, fluorescent, and chemiluminescent 
formats. Finally, multiplexed protein detection was performed in a single dish by applying an 
array of DEX droplets containing different primary antibodies. ATPS-immunocytochemistry can 
be further adapted to perform multiplex ATPS-immunohistochemistry to aid in biomarker 
discovery and patient stratification, as well as to screen for antibody quality, perform high-








Immunohistochemistry (IHC) is a common research technique that uses antibodies to 
detect the presence and localization of specific proteins. The process is used by both basic 
research scientists and clinicians to investigate prognostic factors and predict therapeutic 
outcomes of diseases, as well as to differentially diagnose patients based on the presence (or lack 
thereof) of specific cell morphologies and/or protein expression by the cells of interest (Luongo 
de Matos et al., 2010). Although IHC is readily used, there is a lack of standardization in sample 
processing and interpretation across labs, which makes it difficult to make universally accepted 
conclusions from results. Furthermore, as research and medicine shifts to personalized 
treatments, newer technologies that aid in the above processes will be necessary to achieve this 
paradigm shift (Dietel and Sers, 2006; Wang and Vo-Dinh, 2009).  
One of the ways researchers are advancing such technologies is to implement 
multiplexing, or the ability to detect multiple biomarkers of interest from a single sample. For 
example, DNA microarrays and other genomic prolifers are increasingly being used to 
characterize the genomic status of patients (Shen and Wu, 2009). However, changes in DNA are 
not always replicated at the protein level, which is a more relevant readout since it reflects cell 
behavior and overall physiological response. Therefore, sensitive and accurate multiplex protein-
based assays, such as multiplex IHC, will be even more relevant to the advancement of the field. 
To this end, several research groups have implemented methods with which to perform multiplex 
IHC; multiple antibody labeling (Xing et al., 2007), membrane layering (Gannot et al., 2005), 
microchannels (Kim et al., 2010), and microfluidic probes (Lovchik et al., 2012) have all 
demonstrated the capacity to detect multiple antigens from a single sample. These technologies 
can be applied to early biomarker discovery and validation, where there is a need to analyze 
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large numbers of samples and biomarkers in parallel to identify potential therapeutic targets 
(Sauter et al., 2003), and later in clinical trials, where it is useful to analyze multiple biomarkers 
to stratify patients and analyze their responses to therapeutics, especially when samples are 
limited.  
The multiplex IHC approaches listed above, however, are not without their own 
limitations. Multiple antibody labeling requires highly specific combinations of  antibodies to 
prevent their cross-reactivity, and in the case of fluorescent readouts also requires complex 
combinations of fluorophores and filter cubes to distinguish signals; therefore, with this approach 
it becomes exceedingly difficult to detect more than 2 proteins from the same sample. Membrane 
layering utilizes a stack of functionalized membranes to transfer different individual proteins 
from the sample to each membrane. Unfortunately this approach consumes large amounts of 
reagent and does not provide very detailed transfer features. Finally, although microfluidics 
consume small amounts of expensive reagents and can achieve extremely small sample areas, it 
requires highly specialized equipment and requires technical expertise to operate, making it 
burdensome to adopt into many labs and scale commercially. 
The use of aqueous two-phase systems (ATPSs) to pattern reagents, on the other hand, 
only requires handheld pipettes, consumes microliter volumes of reagents, can be readily scaled, 
and can be easily modified to accommodate various biologics such as transfection reagents 
(Tavana et al., 2009), multiple cell types (Frampton et al., 2013b), and microbubbles (Frampton 
et al., 2013a), among other reagents. This technique was further modified here to spatially 
pattern antibodies over a monolayer of cells to achieve rapid and robust localized detection of 
proteins. Sizes of staining areas and spacing between them can be tailored by selecting the 
appropriate molecular weights and concentrations of polyethylene glycol (PEG) and dextran 
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(DEX) dissolved in solution. Furthermore, because this technique confines antibodies to 
microliter droplets of DEX on the surface of cells and decreases the available void volume, it 
reduces the diffusion distance for antibodies to bind their respective proteins, thereby increasing 
signal intensity and decreasing the incubation time required to stain cells. ATPS-based staining is 
also highly versatile and can be used to pattern primary and/or secondary antibodies and can be 
used with colorimetric, fluorescent, or chemiluminescent readouts. Due to the ease with which 
ATPS-ICC is performed and the versatility of the assay, we envision the technique could be a 
powerful tool in drug development for multiplex protein detection for biomarker discovery, 
patient diagnosis, and to explain patient response to therapeutic protocols. 
 
2.2 Materials and Methods 
2.2.1 Antibody partitioning in PEG/DEX ATPSs 
Partitioning of primary IgG antibodies (cytokeratin 7 (CK7), 18-0234, Life Technologies; 
cytokeratin 8 (CK8), 18-0185Z, Life Technologies; leukocyte common antigen (LCA), 180367, 
Life Technologies) and a biotinylated detection antibody (B-2763, Life Technologies) was 
determined by dot blot. Briefly, 1:500 dilutions of antibodies were added to Eppendorf tubes 
containing 10% w/w PEG 35 kDa (81310, Sigma) and 10% w/w DEX 500 kDa (DEXT500, 
Pharmacosmos) (total volume, 1 ml). Control tubes contained only PEG and DEX and were not 
enriched with antibodies. The contents of each Eppendorf tube were thoroughly mixed by 
rocking at room temperature for 10 min. The tubes were then centrifuged at 400 rcf at 4° C for 
15 min, which facilitated the complete phase separation and equilibration of the PEG and DEX 
phases. Polyvinylidene fluoride (PVDF) membranes (10413052, Whatman) were soaked in 
methanol for 15 s, water for 2 min and finally PBS for 5 min. Six 0.5 µl samples each of the PEG 
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and DEX phases were dispensed onto the PVDF membranes, which were then blocked in 1% 
BSA for 1 h and washed 4 times with PBS containing 0.05% Tween-20. In the case of 
membranes spotted with solutions containing primary antibodies, membranes were further 
incubated for 1 h with biotinylated goat anti-mouse antibody (1:1000 dilution) in PBS. Following 
another 4 washes, both membranes were incubated with streptavidin-conjugated horseradish 
peroxidase for 1 h, washed 4 times, and incubated with SuperSignal ELISA Femto Maximum 
Sensitivity Substrate (37074, Thermo Scientific). Chemiluminescent signal was detected using a 
FluorChem M (Protein Simple) imaging system. Partition coefficients, defined as the reagent 
concentration in the PEG phase divided by the reagent concentration in the DEX phase, were 
calculated by taking the ratios of chemiluminescent signals from the PEG and DEX spots on the 
PVDF membranes. 
 
2.2.2 Staining characteristics  
A549, H2170, and SK-MES-1 pulmonary epithelial cell lines (CCL-185, CRL-5928, 
HTB-58; ATCC) were maintained in F12, RPMI, and MEM-alpha media, respectively, 
supplemented with 10% FBS (12306C, Sigma) and 1% anti-anti (15240-062, Gibco). To 
demonstrate staining capabilities, cells were plated into 35- or 60-mm dishes and grown to 
confluence over the course of 24 h. Cells were fixed with 4% paraformaldehyde (PFA) for 15 
min, rinsed with PBS, permeabilized with 0.1% Triton X-100 (T-9284, Sigma), and rinsed and 
stored in PBS for future use.  
To demonstrate how staining size was dependent on ATPS characteristics, the following 
ATPSs were formulated from PEG 35 kDa and DEX 500 kDa: 5% DEX and 5% PEG, 10% 
DEX and 10% PEG, and 20% DEX and 20% PEG. Immunocytochemistry (ICC) was performed 
on fixed and permeabilized cells that were treated for 1 h with 1% H2O2 to neutralize intrinsic 
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peroxidase activity, washed with PBS containing 0.05% Tween 20, blocked for 1 h with 1% 
BSA (810683, Millipore), and washed. Localized staining of cells was then performed using 
ATPSs; briefly, DEX phases were enriched with a 1:200 dilution of mouse anti-CK 7 and PEG 
phases enriched to a final BSA concentration of 0.1%, confluent dishes of cells were filled with 
PEG solution, and antibody-enriched DEX droplets were dispensed into dishes using a Matrix 
MultiChannel Equalizer Pipette (Thermo Scientific). Cells were incubated with primary 
antibodies in ATPS for 1 h, washed, incubated for 1 h with 1:400 biotinylated goat anti-mouse 
antibody (B2763, Molecular Probes) in PBS, washed, incubated for 1 h with streptavidin-
conjugated horseradish peroxidase (Strep-HRP), washed, and developed using diaminobenzidine 
(DAB) (750118, Invitrogen). Staining areas were analyzed using ImageJ. 
Time-dependent staining was performed with a similar, but slightly modified protocol. 
Following treatment with H2O2 and blocking with BSA as before, dishes were filled with PEG 
containing 0.1% BSA. Then 0.5 μl droplets of DEX containing 1:200 anti-CK 7 were dispensed 
into dishes and incubated for the following lengths of time: 120, 60, 30, 20, 10, 5, 2.5, and 1 min. 
Dishes were washed, incubated with secondary antibody, washed, incubated with Strep-HRP, 
and washed as before. Finally, signal was developed using SuperSignal ELISA Femto Maximum 
Sensitivity Substrate (PI37074, Fisher Scientific), read on a FluorChem M Digital Imager, and 
images were analyzed for signal intensity using ImageJ. Time-dependent staining characteristics 
were also analyzed for cells incubated with antibodies in the absence of ATPS. In this format, 
cells were fixed and permeabilized in a 96-well dish. The staining protocol was the same as that 
outlined above for ATPS-treated cells in dishes, except with the following modifications: 
individual wells with cells were incubated with 1:200 primary mouse anti-CK 7 in PBS 
containing 0.1% BSA for the prescribed times, and signal was developed by incubating wells 
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with 100 μl ABTS (00-2024, Invitrogen) and read at 415 nm on a Synergy Neo HTS Multi-Mode 
Microplate Reader (Biotek). 
 
2.2.3 Multiplex staining of epithelial cells 
Multiplex staining of epithelial cells was performed with 3 different readout formats: 
colorimetric (with DAB), chemiluminescent, and fluorescent. Following fixation, 
permeabilization, incubation with H2O2, and blocking, dishes were filled with 10% PEG 
containing 0.1% BSA. Mouse anti-human CK 7, anti-human CK 8, and anti-human leukocyte 
common antigen were diluted 1:200 in 10% DEX solutions, which were then dispensed into PEG 
in array format and incubated for 1 h. Dishes were washed and incubated with the appropriate 
secondary antibodies for 1 h. For colorimetric and chemiluminescent readouts, dishes were 
incubated with 1:400 biotinylated goat anti-mouse antibodies, and for fluorescent readouts, 
dishes were incubated with 1:200 FITC-conjugated rabbit anti-mouse antibodies (sc-358916, 
Santa Cruz Biotechnology). For the fluorescent readout, dishes were then washed and imaged 
using an Eclipse TE300 microscope (Nikon), while for colorimetric and chemiluminscent 
readouts, dishes were washed, incubated with Strep-HRP, washed, and developed as previously. 
 
2.3 Results and Discussion 
2.3.1 Antibody partitioning in PEG/DEX ATPSs 
 During ATPS equilibration, antibodies naturally partition based on molecular 
characteristics and phase system properties. After solutions were fully equilibrated, sample 
aliquots were taken from each phase, applied to PVDF membranes, and detected via 
chemiluminescent signals from the aliquots on a FluorChem M Digital Imager. In this format, 
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chemiluminescent signal intensity is proportional to the amount of antibody in solution. By 
dividing signal intensity of the PEG phase by that of the DEX phase, we obtained partition 
coefficients for several different antibodies (Figure 2.1). As can be seen, qualitatively there is no 
visually detectable signal arising from the region of the PVDF membrane where PEG was 
spotted, while there are distinct chemiluminescent signals arising from the regions were DEX 
was incubated. Quantitatively, partition coefficients are <0.072, i.e., virtually 100% of antibodies 
partition to the DEX phase.  
Because antibodies naturally partition to the DEX phase, we can use ATPS technology to 
spot small droplets of DEX containing antibodies on a monolayer of cells to perform localized 
staining (Figure 2.2). In this format, the workflow for ATPS-ICC or ATPS-IHC is very similar to 
traditional non-ATPS methods, but with slight modifications to the antibody incubation steps. 
Therefore, all initial processing steps including fixation, permeabilization, incubation with H2O2, 
and blocking are identical. In the traditional approach, cells are incubated with a bath solution of 
primary antibodies; to perform staining of multiple proteins, different primary antibodies are 
included in solution (Figure 2.2 A, i). Primary antibodies bind uniformly across the cell 
monolayer, and after washing away excess primary antibodies (Figure 2.2 A, ii), cells are 
incubated with secondary antibodies, which bind to their respective primary antibodies, and then 
washed to remove unbound secondary antibodies (Figure 2.2 A, iii). This approach is limited, 
however, because each capture and detection antibody pair must have a distinct species of origin 
and reactivity to prevent antibody cross-reactions. For example, if one wanted to stain for protein 
A and protein B, one could use a mouse anti-protein A and rabbit anti-protein B as the primary 
antibodies, then apply goat anti-mouse and donkey anti-rabbit secondary antibodies. If, however, 
a mouse anti-protein A and mouse anti-protein B were used, the secondary antibody wound bind 
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to both primary antibodies and it would be impossible to distinguish signals produced by the 
individual proteins. 
ATPS-ICC and ATPS-IHC, on the other hand, confine different primary antibodies to 
their respective DEX droplets (Figure 2.2 B, i). In this format, because antibodies partition to 
DEX and cannot diffuse outward, they only bind to proteins in the area over which the DEX 
droplet spreads (Figure 2.2 B, ii). Therefore, even when a bath solution of secondary antibody is 
applied (and subsequently washed away), signal is only produced in the regions where primary 
antibodies are spotted (Figure 2.2 B, iii). Unlike the traditional format, this approach enables the 
use of a single species of primary antibodies and a single detection antibody to detect multiple 
proteins at different locations, i.e., one could use mouse anti-protein A, mouse anti-protein B… 
mouse anti-protein Z and a goat anti-mouse secondary antibody. This is the case because even 
though the secondary antibody binds to all primary antibodies, because each primary antibody is 
localized, signals are spatially resolved.  
 
2.3.2 Staining characteristics 
 Using the ATPS-based approach described above, we characterized staining properties 
based on ATPS concentrations, droplet volumes, and incubation times. ATPSs of PEG 35 kDa 
and DEX 500 kDa were formulated at concentrations of 5, 10, and 20%, and PEG and DEX were 
further enriched with 0.1% BSA and primary antibody, respectively. During the primary 
antibody incubation step, 0.5, 1, and 2 μl drops of antibody-containing DEX were dispensed into 
PEG solutions, followed by washing and development (Figure 2.3 A). As expected, higher 
concentrations of polymers (due to greater interfacial tensions between the solutions) and smaller 
droplet volumes led to smaller staining areas (Figure 2.3 B). For the 10% and 20% ATPSs at the 
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lower volumes, however, differences in staining areas were marginal, and because the 20% 
solutions are much more viscous and can be more difficult to pipette and wash from dishes, 10% 
solutions may be more ideal for some applications. Furthermore, although ATPSs with other 
molecular weights of PEG and DEX were not investigated, results would be expected to follow a 
similar pattern; for the same concentrations tested here, lower molecular weights would be 
expected to have larger staining areas due to lower surface tensions between the solutions that 
would facilitate greater droplet spreading. 
 ATPSs also seem to facilitate more complete binding of antibodies to proteins (Figure 
2.4). Antibodies were incubated with cells for times ranging from 1 to 120 min; for the ATPS 
format, signal was developed with chemiluminescent substrate and read on a digital imager, 
while for the non-ATPS format, signal was developed with ABTS and read on a plate reader. 
Because the readout formats were different, raw signal intensities varied by several orders of 
magnitude. Therefore, to compare binding kinetics, signal intensities were normalized against the 
signal intensity produced at the 120 min time point. Data were then fit with Michaelis-Menten-
like equations, whose corresponding curves were also plotted. Based on these fits, maximum 
normalized signal intensities at t=∞ were 1.08 and 0.92 for ATPS and non-ATPS staining, and 
the times to reach 50% and 90% of maximal signal intensity occurred at approximately 2 and 19 
min and 3.5 and 32 min for the ATPS and non-ATPS formats, respectively. This seems to 
indicate that the microdroplet confinement causes more antibodies to bind cells and to do so 
more rapidly, which can be attributed to a shift in equilibrium binding kinetics and a restriction 
to diffusion caused by antibody partitioning to the small DEX droplets. 
 Finally, several non-traditional staining proofs-of-concept were performed to demonstrate 
the versatility and fidelity of this approach. First, ATPS-localization of secondary antibodies was 
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performed. In the previous formats, ATPS was used to localize primary antibodies to distinct 
regions and secondary antibodies were bath-applied; in this “reverse” format, primary mouse 
antibody was applied uniformly in PBS, followed by ATPS spotting of biotinylated goat anti-
mouse secondary antibody. Washing and signal development occurred as before to produce 
colorimetric signals (Figure 2.5 A). This idea was taken a step further to spot both the primary 
and secondary antibodies using ATPS. Here, we first spotted and incubated primary antibody 
(Figure 2.5 B, i). Following the necessary washing, ATPS was then used to spot secondary 
antibody so that the DEX droplet containing secondary antibody partially overlapped the area 
where primary antibody was spotted (Figure 2.5 B, ii), much like a Venn diagram. When signal 
was finally developed, it was only localized to the central region where both primary and 
secondary antibodies were incubated (Figure 2.5 B, iii). These proofs-of-concept are important 
because they highlight the need to have both primary and secondary antibodies present to 
produce signal and that antibody binding is specific. Finally, ATPS-based spotting of antibodies 
enables spatial control that can be used to selectively localize antibodies in discrete patterns (here 
droplets spell “IHC”) with various readout formats (Figure 2.5 C). 
 As can be seen, ATPS-ICC offers several advantages over traditional approaches. 
Discrete localization of antibody spots enables researchers and scientists to conserve precious 
and expensive antibodies. Whereas traditional staining may require > 1 ml antibody solution, this 
approach can apply antibodies in < 1 µl droplets, thereby conserving antibodies by 1000-fold. 
Furthermore, ATPS enables greater amounts of antibody binding and more rapid binding of 
antibodies than traditional approaches, thereby reducing the time required to perform the assay. 
Finally, the ability to pattern primary and secondary antibodies, as well as to combine the assay 
with various readout formats, enables researchers to tailor the system to suit their needs. For 
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example, in the development of antibodies to detect a protein of interest, researchers could use 
ATPS to spot several different types of antibodies side-by-side to compare binding efficiency 
and/or signal production (while simultaneously conserving antibodies) to select the most optimal 
antibodies for their purposes. Furthermore, by combining this approach with various signal 
formats such as fluorescence or chemiluminescence, it may be easier to quantitatively analyze 
expression levels instead of relying on qualitative and arbitrary analyses that are typical of 
traditional ICC and IHC. 
 
2.3.3 Multiplex staining of epithelial cells 
Multiplex staining is performed in the same manner as single staining, except DEX 
droplets are enriched with different primary antibodies. Epithelial cells were stained for CK 7, 
CK 8, and LCA, which were chosen as positive (cytokeratins) and negative stains (LCA) (Figure 
2.6). As can be seen, signal was localized and only produced for CK7 and CK8, while no signal 
was produced at LCA spots, which is expected because LCA is a marker of leukocytes and 
hematopoietic progenitor cells and should not be expressed in epithelial cells. Side-by-side 
analysis with immunofluorescently-labeled secondary antibodies confirmed the staining patterns 
produced with DAB.  
Multiplex staining could be especially interesting in the context of biomarker discovery 
and patient stratification. Side-by-side staining of cells with known and potential biomarkers of 
disease would enable researchers, clinicians, and drug developers to catalog larger panels with 
which to identify diseases and gauge their progression. During the clinical trials stage, once a 
panel of biomarkers has been identified for a disease, multiplex ATPS-IHC would be a useful 
method that would enable researchers to better stratify patients and predict patient responses to 
treatments. For example, panels of biomarkers that include p63, CK5/6, and TTF-1 have been 
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shown to be useful in differentiating between squamous cell carcinoma and small cell lung 
cancer. In this case, p63 and CK5/6 are highly expressed in squamous cell carcinomas, while 
TTF-1 is rarely expressed (and vice-versa for small cell lung cancer) (Mani and Zander, 2012). 
These types of multiplexed biomarker detection methods are growing increasingly useful in 
differential patient diagnosis and will be especially useful in identifying subsets of patients that 




ICC and IHC are well-established techniques, and IHC is commonly used in biomarker 
discovery and to diagnose patients. These techniques, however, are limited by their lack of 
standardization, qualitative nature of the readouts, and limited ability to detect multiple 
biomarkers from a single sample. Many techniques have been developed to perform multiplex 
protein detection from immunohistochemical samples, but they often require highly technical 
operation of specialized equipment and/or extensive validation of antibody specificity. 
ATPS-ICC, demonstrated here, should be easy to translate to ATPS-IHC. Unlike 
previously developed multiplex techniques, this approach only requires polymer-enriched 
solutions and pipettes to be performed; therefore, due to the low technical skill required it should 
be readily adoptable into many laboratory settings. Furthermore, in the context of clinical labs 
that require rapid and automated staining of samples, ATPS-based multiplex staining could also 
be implemented due to its easy interfacing with automated plate handlers and liquid dispensers. 
Interfacing the ATPS-based approach with liquid handlers could also enable even greater 
precision in staining; we demonstrated that we were able to achieve staining areas of 
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approximately 2 mm2 with a handheld multichannel pipette, but liquid handlers capable of 
delivering <0.5 µl of fluid could produce even smaller staining areas that enable higher degrees 
of multiplexing. We further demonstrated here that ATPS-ICC can reduce assay time and 
increase signal intensity; whereas traditional staining required longer than 30 min to reach 90% 
of the maximum signal intensity, the ATPS approach, which confines antibodies to the surface, 
reduced this time to less than 20 min.  
ATPS-ICC and ATPS-IHC could be valuable tools in the drug development process. 
During the biomarker discovery stage, these approaches could be used to perform side-by-side 
analysis of validated biomarkers with potential new biomarkers of interest. Similarly, as new 
antibodies are generated to detect biomarkers, a similar side-by-side analysis could be used to 
compare antibody selectivity and signal generation capabilities to select the highest affinity and 
highest-signal producing antibodies. Furthermore, during clinical trials, it would be beneficial to 
have multiple biomarker analysis methods to more definitively stratify patients and predict 
and/or explain patient response to therapeutic regimes. As a potential future avenue, with the 
appropriate liquid dispensing tools, this approach could be used to deliver antibodies to a single 
cell or small groups of cells to perform in-cell ELISA to directly quantify protein expression. 
This will be an important area of basic and translational research in drug development because it 
is now apparent that single cells within a larger population (even if they are the same cell type) 
can differ dramatically, and therefore it will be crucial to characterize and understand these 
differences to better understand (patho)physiology and to develop efficacious therapeutics. 
Finally, as the industry shifts from small pharmaceutical compounds to biological therapeutics, 
one could envision implementing this approach as a high-throughput and/or multiplexed in vitro 
screening approach for recombinant antibodies. After plating a monolayer of cells (cell lines or 
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primary cells), an array of antibody-containing DEX droplets could be spotted onto the dish 
against the desired target proteins; droplets could contain either a single antibody or a 
combination of antibodies, and subsequent cell responses could be studied.  
The immediate applications for ATPS-ICC and ATPS-IHC in biomarker discovery and 
validation and patient stratification will require further technical validation and the development 
of scoring systems to be implemented in clinical settings, but these applications, as well as other 
potentially exciting screening uses make it especially promising as a next-generation technology 







Figure 2.1: Antibody partitioning in a PEG and DEX ATPS. A representative 
chemiluminescent image of a PVDF membrane spotted with CK8 antibodies is shown. 
Qualitatively there is no signal arising from the regions of the membrane where PEG aliquots 
were spotted, while there are clearly signals arising from the regions where DEX was dispensed. 
After subtracting background signal from the regions of interest, partition coefficients were 
calculated for CK7, CK8, LCA, and biotinylated goat-anti mouse secondary (20) antibodies by 
averaging the signal intensities from six individual spots from each phase and taking the ratios of 





Figure 2.2: Comparison of workflows of ICC and IHC with ATPS-ICC and ATPS-IHC. A) 
Traditional staining format. i) multiplex protein detection is performed by incubating a fixed and 
permeabilized monolayer of cells with a homogeneous bath solution containing the primary 
antibodies of interest; ii) after rinsing unbound antibodies, primary antibodies are bound across 
the entire monolayer of cells; iii) following a wash, secondary antibodies are applied and bind to 
their respective primary antibodies. In this format, each primary/secondary antibody pair must be 
raised with different species reactivity to prevent antibody cross-reactions from occurring and 
each must have a different signal-producing readout so as to be able to distinguish between the 
proteins. B) ATPS-ICC or ATPS-IHC format. i) multiplex protein detection is performed by 
incubating a fixed and permeabilized monolayer of cells with an ATPS that localizes the primary 
antibodies of interest to specific regions; ii) after rinsing, primary antibodies are bound only to 
areas over which DEX spread; iii) following a wash, a single secondary antibody can be applied 
to produce signal. In this format, primary antibodies can all be raised in the same species and a 
single secondary antibody can be applied (with a single enzyme conjugation) because antibody 








Figure 2.3: Droplet volume- and polymer concentration-dependent staining areas. A) 
Representative images of monolayers of SK-MES-1 cells in 35 mm dishes stained with 0.5 µl 
CK7 antibody-containing DEX droplets from ATPSs of PEG 35 kDa and DEX 500 kDa at 
concentrations of 20 (left), 10 (middle), and 5% (right). B) Signal areas were quantified using 
ImageJ; as expected, signal areas were smaller for higher concentrations of polymers and smaller 





Figure 2.4: Time-dependent staining intensity of A549 cells. A) Representative image of a 35- 
mm dish of epithelial cells stained with DEX droplets containing CK7 for 120, 60, 30, 20, 10, 5, 
2.5, and 1 min (left to right), respectively. B) Signal intensities were normalized against the 
intensity at 120 min so as to be able to compare kinetics of the ATPS- and non-ATPS-based 
systems. Points were fit with Michaelis-Menten-like curves, which show that ATPS-based 
staining causes higher maximum signal intensity and causes those maximum signals to be 





Figure 2.5: Other staining capabilities with ATPS-ICC. A) After applying a uniform solution 
of primary antibody, ATPS can be used to spot DEX droplets of secondary antibodies, which 
also results in localized staining. B) Both primary (i) and secondary (ii) antibodies can be spotted 
sequentially, which produces signal that is localized to the interior and overlapping region where 
both antibodies were localized in a Venn diagram format (iii). C) ATPS-based staining can be 
applied with high degrees of spatial control, as demonstrated by the spelling of "IHC," and can 







Figure 2.6: Multiplex staining of epithelial cells. Epithelial cells were stained for CK7, CK8, 
and LCA. As expected, signal was produced in regions where cytokeratins were localized (green 
dashed circles), while no signal was generated at regions where LCA was spotted (red dashed 
circles). Fluorescent staining from another dish confirmed the stain was specific for cytoskeletal 
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Cell Co-Culture Patterning Using Aqueous Two-Phase Systems 
This chapter describes the use of a PEG/DEX ATPS for patterning monocultures and co-cultures 
of cells. The cloud-point method was used to construct binodal curves for several types of serum-
free and 10% serum-enriched media. PEG 35 kDa and DEX 500 kDa were then tested at 1x, 2x, 
and 3x their critical concentrations, the concentrations below which two phases do not form, to 
determine the conditions that enabled effective cell patterning, that did not adversely affect cell 
morphology, and that did not facilitate serum precipitation from solution. Cells were exclusion- 
and island-patterned in monoculture and monitored for proliferation and migration over the 
course of 72 h. Exclusion and island patterning were combined to pattern hepatocytes and 
fibroblasts in co-culture, and hepatocytes were then qualitatively analyzed for albumin 
production over 96 h. These techniques demonstrate a simple and scalable method with which 
cells can be patterned for high-throughput cell migration analysis and/or patterned to achieve 







The human body is made up of billions of cells that have arisen from a single cell in a 
complex and orchestrated series of steps including cell division, growth, migration, and 
differentiation. Cells are organized into a series of organ systems that each performs a set of 
specific functions. Within a specific organ, cell-cell, cell-extracellular matrix, and cell-
environment interactions are finely orchestrated to ensure the organ functions properly 
(Astashkina et al., 2012); furthermore, each organ system interacts with others via mechanical, 
chemical, and electrical signals to maintain the body in homeostasis. However, when signaling 
becomes aberrant, or when the body is assaulted with damaging external stimuli and the body 
cannot return itself to homeostasis, disease results. To better understand human physiology and 
pathophysiology, and to develop therapeutics directed against pathophysiological targets, 
researchers and clinicians use a range of in vitro and in vivo approaches.  
Although in vivo testing is conducted on whole living organisms, and is therefore thought 
to more accurately reflect physiological responses, there are many problems and drawbacks 
associated with this approach including ethical challenges, prohibitive costs (Perkel, 2012), and 
lack of translatable results from animals to humans (Smith, 1991). In vitro testing, on the other 
hand, takes a reductionist approach by isolating and studying part of an organism in a controlled 
manner. Cell monocultures, cell co-cultures, and organ explant cultures are all used with varying 
degrees of success to analyze cell behavior and mechanisms of disease. Although monocultures 
of cells in polystyrene dishes, especially immortalized cells, are relatively straightforward, it has 
become apparent that these types of cells are morphologically and physiologically very different 
from their in vivo counterparts (Allen et al., 2005; Donato et al., 2008) and that continual 
passaging promotes further genetic drift (Yamasaki et al., 2009). On the opposite end of the 
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spectrum, organ explant cultures maintain the native cell and tissue architecture and are therefore 
more physiologically relevant; however, they can only be maintained in culture for several days 
and there is limited ability to deduce the spatial distribution of biomolecules, making it difficult 
to gain mechanistic insights into physiology and pathophysiology (Astashkina et al., 2012). 
The middle ground between these two techniques is to spatially pattern co-cultures of 
cells; although reductionist in nature, this approach still maintains more complex heterocellular 
and cell-matrix interactions while also enabling researchers to more easily visualize and analyze 
cell responses, thereby providing mechanistic insights into cell responses. To this end, 
microcontact printing (Falconnet et al., 2006), surface topography (Lim et al., 2007), inkjet 
printing (Ringeisen et al., 2006), microfluidic laminar flow patterning (Takayama et al., 1999; 
Berthier et al., 2011), and stencil-based patterning (Wright et al., 2007) have all been used. 
However, these techniques require user expertise, specialized equipment, and may damage cells 
during the printing process, making them difficult to implement in many laboratory settings. 
In contrast to other methods for cell patterning, ATPS cell patterning is easy to learn and 
only requires rudimentary knowledge about the polymers themselves and the ability to perform 
cell culture and use a micropipettor. To this end, we have utilized the interfacial properties and 
partitioning effects of ATPSs to pattern several types of cells (Frampton et al., 2011; Tavana et 
al., 2010; Tavana et al., 2011a; Tavana et al., 2011b). Here we report a detailed protocol for 
generating patterned cell cultures using the ATPSs described in our previously-published 
applications (Frampton et al., 2013). This approach enables the generation of arrays of cell 
exclusion zones or cell islands for high-throughput migration assays; these techniques can also 
be combined to rapidly generate co-cultures of cells such as liver-fibroblast cell co-cultures. 




3.2 Materials and Methods 
3.2.1 Construction of Binodal Curves and Cell Compatibility 
 Cell culture media were enriched with PEG 35 kDa and DEX 500 kDa to various starting 
concentrations of each in 50 ml conical tubes (Figure 3.1, red circles). Solutions were gently 
rocked to dissolve polymers, at which point solutions appeared cloudy, indicating that multiple 
phases were present in solution. Polymer solutions in conicals were then incubated in a vertical 
position at room temperature for 20  min to verify phase separation occurred and two phases co-
existed. Additional media was incrementally added to the conicals and the process of mixing and 
equilibrating was repeated until the solution no longer appeared cloudy and no longer phase-
separated when incubated in the vertical position, indicating that the threshold for phase 
separation had been reached. Based on the initial masses of the added polymers as well as the 
final mass of the solution after adding media, the weight percentage of each polymer at which 
phase separation no longer occurred was calculated. This process was repeated for various initial 
starting concentrations, and final weight percentages of DEX and PEG were plotted on the x- and 
y-axes and fit with a 3-parameter rational function to describe the binodal curves. 
 Based on the binodal curves that were achieved for PEG 35 kDa and DEX 500 kDa, the 
critical point concentrations (the combination of lowest concentrations of polymers that still 
enable the formation of an ATPS) of each polymer were determined. The critical point 
concentrations and 2x and 3x critical point concentrations were then tested for their effects on 




3.2.2 Monoculture Patterning and Cell Migration Analysis  
To demonstrate exclusion patterning (Figure 3.2, left), first, separate polymer solutions of 
5.0% wt/wt PEG and 12.8% wt/wt DEX in DMEM were prepared. HeLa cells were labeled with 
CellTrackerTM Green (C2925, Molecular Probes), pelleted, and resuspended in PEG solution to a 
concentration of 375,000 cells/ml. Using a micropipettor, 0.5 μl droplets of DEX were pipetted 
into the bottom of a 48-well plate in 2x2 array format and dehydrated at room temperature. 
Following dehydration, 200 μl cell suspension in PEG was pipetted into each well of a 48-well 
plate and incubated in a humidified 5% CO2 incubator at 37 ˚C for 12 h to allow cell attachment. 
Following cell adherence, polymer solutions were aspirated from each well, wells were washed 
three times with PBS, and 400 μl fresh growth medium was added to each well. Cells were 
returned to the incubator and monitored over the course of 72 h and fluorescent images were 
acquired at 24 h intervals to analyze closure of the circular void area. 
To demonstrate island patterning (Figure 3.2, middle), first separate polymer solutions of 
5.0% wt/wt PEG and 12.8% wt/wt DEX in DMEM were prepared. HeLa cells were labeled with 
CellTrackerTM Red (C34552, Molecular Probes), pelleted, and resuspended in DEX solution to a 
concentration of 10,000 cells/μl. Using a micropipettor, 0.5 μl droplets of cell suspension in 
DEX were pipetted into the bottom of a 48-well plate in 2x2 array format. To prevent 
dehydration, 200 μl PEG solution was immediately and gently added to each well so as not to 
disrupt the DEX droplets. Plates were then incubated in a humidified 5% CO2 incubator at 37 ˚C 
for 12 h to allow cell attachment. Following cell adherence, polymer solutions were aspirated 
from each well, wells were washed three times with PBS, and 400 μl fresh growth medium was 
added to each well. Cells were returned to the incubator and monitored over the course of 72 h, 
with fluorescent images being acquired at 24 h intervals to analyze expansion of the cell area. In 
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each instance, fluorescent images were acquired using a Nikon TE300 microscope and images 
were analyzed using ImageJ. 
 
3.2.3 Co-Culture Patterning and Hepatocyte Albumin Production 
To demonstrate the ability to use ATPS to achieve robust co-cultures (Figure 3.2, right), 
the techniques for exclusion- and island-patterning were combined. Like before, separate 
polymer solutions of 5.0% wt/wt PEG and 12.8% wt/wt DEX in DMEM were prepared. For 
proof of concept, 1 group of HeLa cells was labeled with CellTrackerTM Green (C2925, 
Molecular Probes), pelleted, and resuspended in PEG solution to a concentration of 375,000 
cells/ml, while a 2nd group was labeled with CellTrackerTM Red (C34552, Molecular Probes), 
pelleted, and resuspended in DEX to a concentration of 10,000 cells/μl. Using a micropipettor, 
0.5 μl droplets of red-labeled cell suspension in DEX were pipetted into the bottom of a 48-well 
plate in 2x2 array format. Immediately thereafter, 200 μl green-labeled cell suspension in PEG 
was pipetted into each well of a 48-well plate and incubated in a humidified 5% CO2 incubator at 
37 ˚C for 12 h to allow cell attachment.  
In a separate demonstration more relevant to cell functionality, the same approach as 
above was used with slight modifications. HepG2/C3A (HB8065, ATCC) hepatocytes were 
pelleted and resuspended in DEX to a concentration of 10,000 cells/µl. A second cell type, NIH 
3T3 fibroblasts (CRL1658, ATCC), was growth arrested for 2 h with 10 µg/ml mitomycin C 
(M4287, Sigma); this step was necessary due to the rapid proliferation of this cell type to prevent 
it from overgrowing the HepG2/C3A cells. They were then pelleted and resuspended in PEG to a 
concentration of 750,000 cells/ml. Using a micropipettor, 0.5 µl droplets of hepatocyte cell 
suspension in DEX were pipetted into a 3x3 array in a 35 mm dish. Immediately thereafter, 
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either 1 ml fibroblasts in PEG or 1 ml PEG alone were added to the dish and incubated in a 
humidified 5% CO2 incubator at 37 ˚C for 12 h to allow cell attachment. After 24, 48, and 96 h, 
cells were fixed in 4% paraformaldehyde (19943, Affymetrix) for 15 min at room temperature, 
washed, permeabilized with 0.1% Triton X-100 (T9284, Sigma) for 15 min at room temperature, 
incubated with horseradish peroxidase-conjugated goat anti-human albumin (E80-129, Bethyl 
Laboratories) for 2 h, washed, and finally incubated with diaminobenzidine (750118, Novex) to 
develop color. Dishes were then imaged with brightfield microscopy on a Nikon SMZ8000 
stereomicroscope. 
 
3.3 Results and Discussion 
3.3.1 Construction of Binodal Curves and Cell Compatibility 
 Based on results from the cloud point method experiments, 6 binodal curves were 
constructed for the following common media: DMEM, DMEM+10% fetal bovine serum (FBS), 
F12, F12+10% FBS, RPMI, and RPMI+10% FBS (Figure 3.1). As can be seen, in this case the 
binodal curves were nearly the same for all media used; however, it is important to determine 
this experimentally since the characteristics of the binodal curve are dependent on polymer 
characteristics as well as temperature, pH and ionic content. 
 From previous work, it was determined that the critical concentrations for PEG 35 kDa 
and DEX 500 kDa were 2.5% w/w and 3.2% w/w, respectively. Based on these critical 
concentrations, we tested nine phase system combinations for patterning, as shown in Table 1. 
When combining separate solutions enriched with PEG and DEX, there is a small flux of each 
polymer to the opposite phase as the system equilibrates. Therefore, after some combinations of 
PEG and DEX were combined, they did not form stable ATPSs and were therefore not useful for 
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patterning (Table 1A, x). Other polymer combinations produced recognizable patterns of cells, 
but were not uniform enough for experimentation (Table 1A, x/√). Useful polymer formulations 
formed exclusion zones or islands that were nearly devoid of cells in the non-patterned regions 
(Table 1a, √). 
In addition to patterning capabilities, polymer effects on cell morphology and serum 
precipitation were analyzed. At 10% PEG, cell morphology was abnormally spindle-like after 24 
h, and cells had a diminished ability to attach to the culture surface (Table 1B, x); on the other 
hand, morphology and attachment were normal for 2.5% and 5% PEG (Table 1b, √). At 10% 
PEG, serum also precipitated from the culture medium (Table 1C, x), suggesting that abnormal 
cell morphology and attachment in 10% PEG may be related to problems with access to serum. 
Based on these results, combinations of 5% PEG/6.4% DEX and 5% PEG/12.8% DEX 
were considered well suited for cell patterning; however, 12.8% DEX produced more uniform 
cell patterning and was therefore selected for further experiments. 
 
3.3.2 Monoculture Patterning and Cell Migration Analysis 
 Using the aforementioned patterning techniques, patterned monocultures of cells were 
successfully achieved. Exclusion- and island-patterned cells were assessed for proliferation and 
migration over 3 d (Figure 3.3). After 3 d, HeLa cells closed exclusion zones to approximately 
1/3 their initial size (Figure 3.3 A-C), while island-patterned HeLa cells expanded outward from 
their initial area by approximately 50% (Figure 3.3 D-F).  
 Although not performed here, it would be easy to extend these types of patterned cell 
cultures to screen for potential therapeutic compounds. For example, by patterning an array of a 
single cell type in the island format in a single well, it is possible to consider each of the islands 
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as an individual sample in the population and therefore increase the statistical power of the test. 
On the other hand, it would also be possible to pattern islands of cell colonies with different 
expression profiles. In this format, when a therapeutic compound is applied to a single well, each 
island would likely respond differently, and researchers could further investigate the cell sub-
populations to explain the inconsistencies. This could be especially useful in studies involving 
rare primary patient samples such as lung cancers; due to the rare nature of these samples, it 
would be unreasonable to spread them across many wells. Furthermore, because of tumor 
heterogeneity, cells from different locations within the tumor will respond dissimilarly to 
therapeutics and biomolecules. By using an ATPS patterning technique, researchers could 
conserve samples and further investigate differences in responses of cell and/or tissue 
subpopulations to treatments. 
 
3.3.3 Co-Culture Patterning and Hepatocyte Albumin Production 
Island and exclusion patterning techniques were successfully combined to create 
patterned co-cultures of HepG2/C3A cells, a hepatocellular carcinoma cell line that is commonly 
used to model hepatocyte biology, and NIH 3T3 fibroblasts that were growth-arrested with 
mitomycin C (Figure 3.4). Over 4 d, hepatocytes maintain their localization and colony shape 
(Figure 3.4 A). By placing an array of DEX droplets in the same plate and surrounding them 
with fibroblasts, it is possible to grow these cells in a format that is potentially useful for 
multiplexed and/or high throughput studies (Figure 3.4 B). Staining for albumin, a marker of 
hepatocyte functionality, was performed for hepatocytes patterned in monoculture in the island 
format as well as hepatocytes island-patterned among a layer of fibroblasts (Figure 3.4 C). 
Although qualitative in nature, albumin staining suggests that the hepatocytes in the co-culture 
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format are healthier and more functional, which could be attributed to the more physiologic 
juxtacrine signaling and cellular organization within the dish. 
This brief demonstration highlights the potential future capabilities of this technique in 
drug screening and tissue engineering. In terms of drug screening, co-culture patterning can be 
used to create better organ-mimetic systems with more physiologically relevant signaling and 
responses to external stimuli. By using such platforms early in the screening process, researchers 
can make more informed decisions regarding a compound’s potential future efficacy and off-
target effects, thereby enabling more successful translation in clinical trials. This method may 
also be effective in tissue engineering strategies to enable researchers to easily pattern multiple 
cell types in physiologically-relevant configurations that optimize cell-cell and cell-matrix 
interactions to promote regeneration and/or restore function in diseased tissues. 
 
3.4 Conclusions 
An ATPS of PEG 35 kDa and DEX 500 kDa was characterized in terms of binodal 
curves for 6 different media types; varying concentrations of these polymers in DMEM were 
used to analyze their ability to effectively pattern cells, their effect on cell morphology, and their 
effect on serum solubility and precipitation. It was determined that 10% PEG was not useful for 
patterning cells due to its negative impact on cell morphology and tendency to precipitate serum 
out of solution. On the other hand, 2.5% PEG was also not useful for patterning due to the fact 
that it often resulted in poorly-defined patterns of cells. Therefore, a polymer combination of 5% 
PEG and 12.8% DEX was selected for further patterning demonstrations, such as exclusion and 
island patterning of HeLa cells and co-culture patterning of HepG2/C3A and NIH3T3 cells. 
Patterned HeLa cells were analyzed for proliferation and migration over time and it was 
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demonstrated that for exclusion patterning, the void area decreases, while for island patterning 
the cell area increases. Co-cultures of HepG2/C3A hepatocytes and NIH3T3 fibroblasts seemed 
to result in greater albumin production by hepatocytes, suggesting that patterned co-cultures may 
be more physiologically relevant than hepatocytes patterned in monoculture. 
Aqueous two-phase patterning of cells is simple and easily adapted to almost any 
biological laboratory setting. This method allows any researcher with access to a typical cell 
culture lab (access to a hood, CO2 incubator, and micropipettes) and the aforementioned 
polymers to reproducibly pattern cells in monoculture and co-culture. This is in contrast to other 
patterning techniques, such as patterning of extracellular matrix (Johnson et al., 2011), inkjet 
printing (Moon et al., 2007), and patterning by laminar flow in microfluidic devices (Takayama 
et al., 1999), which are technically challenging, require expensive and specialized equipment, 
and also may necessitate access to cleanroom facilities, making them burdensome to adopt in 
many labs.  
Although ATPS patterning can be easily performed using a micropipette (as presented 
here), it can also be implemented with automated printing equipment to facilitate rapid 
generation of more complex, more precise, and/or higher throughput arrays (e.g., liquid handling 
robots and acoustic droplet ejection). For example, researchers can add small molecules that 
modulate cell proliferation and/or migration to wells containing an array of island-patterned cells 
or an array of exclusion voids; in doing so, researchers would have a substantially larger sample 
size, thereby allowing them to reach statistical significance with fewer iterations of testing and 
less consumption of extremely expensive biologics and small chemical compounds. Furthermore, 
it is conceivable that many subpopulations of cells could be cultured with a common feeder layer 
to investigate the impact of paracrine and juxtacrine signaling of many cell types grown together 
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in a single cell culture setup. Finally, tissue engineering applications frequently required spatial 
localization of one or more cell types. It may be possible to adapt this technique for use in 
patterning cells in order to produce more physiologically relevant tissue engineered disease 
models or to pattern cells on implantable materials for clinical applications. This would be 
especially interesting in drug discovery, where researchers seek techniques and/or assays whose 
results translate to actual human physiological responses and could be used to make earlier go/no 




Figure 3.1: Binodal curves for serum-free and serum-enriched media. The polymer 
concentrations at which an ATPS can form can be extrapolated from experimentally determined 
binodal curves. Solutions with polymer concentrations above and to the right of the curves form 
two phases, while those below and to the left form one phase. These binodal curves were 
constructed using the cloud point method by preparing concentrated starting solutions of PEG 
and DEX (red circles) and diluting them with the appropriate media. Points on the binodal curve 
are determined when solutions no longer phase separate. Data points were fit with a 3-parameter 






Figure 3.2: ATPS patterning techniques of cells. A) DEX droplets are pipetted onto the 
surface of a polystyrene dish without cells (left) or with cells (middle, right). B) PEG with cells 
(left, right) or without cells (middle) is then added over top of the DEX droplets. C) After 
overnight incubation, polymer solutions are washed away and dishes are filled with growth 
medium. D) Depending on the selected format, cells will be exclusion-patterned (left), island-
patterned (middle), or combined into co-culture format (right). In these images, HeLa cells were 






Figure 3.3: Migration and proliferation of monocultures of patterned cells. A) Exclusion-
patterned HeLa cells 1 day after patterning. B) Exclusion patterned HeLa cells 3 days after 
patterning. C) Cells proliferate and migrate, significantly reducing the size of the exclusion zone. 
D) Island-patterned HeLa cells 1 day after patterning. E) Island-patterned HeLa cells 3 days after 
patterning. F) Cells proliferate and migrate outwards, significantly expanding the size of the 
island. Images were quantified using ImageJ software to measure the cell clearing and cell island 






Figure 3.4: Albumin production from patterned hepatocytes in monoculture and co-
culture. A) HepG2/C3A remain viable for at least 4 days in culture. B) A 3x3 array of 
hepatocyte islands were patterned among a sheet of growth-arrested NIH 3T3 fibroblasts. 
Multiple islands can be arrayed in a single dish with potential for multiplexed or high throughput 
assays. C) Compared to non-co-cultured island patterns, the co-cultured cells seem to display 
slightly higher levels of albumin production (brown staining), as evident from qualitative 





Table 3.1: Patternability of ATPSs. A) ATPS formulations that can be used for patterning are 
indicated by √, those that cannot are indicated by x, and those that form poorly-defined patterns 
are indicated by x/√. B) Formulations that retain normal cell morphology and attachment 
properties are indicated by √, those that cannot are indicated by x. C) Formulations that resulted 
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Aqueous-Two Phase Localization of Trypsin for in vitro Cell 
Migration Assays 
This chapter describes the development and application of an ATPS for in vitro wound assays 
that is free of cell damage and can be implemented in a variety of cell culture settings. The 
process localizes trypsin to small regions on a monolayer of cells, and subsequent trypsin 
digestion and washing results in circular wound areas into which cells proliferate and migrate. A 
fluorescein isothiocyanate (FITC)-conjugated casein assay was utilized to detect trypsin activity 
and partition characteristics in various ATPSs. Although several ATPSs were investigated, a 
PEG/DEX ATPS was selected as the base system with which to perform subsequent in vitro 
trypsinization. In vitro wound assays were performed on A549 cells cultured in 6-well plates and 
6-well transwells. The contact-free nature of the ATPS enables the system to be applied to new 
and more physiologically relevant substrates such as transwell inserts and potentially soft gels; 
furthermore, the flexibility with which the system can be implemented and its ease of use open 





Cell migration is important in many physiological phenomena including developmental 
morphogenesis, immune response, and wound healing. During these processes, cells respond to 
extracellular directional stimuli in their environment and transduce those signals into 
intracellular responses that lead to migration. Single cell in vitro assays, such as microfluidic 
gradient generators (Irimia et al., 2006) and constant-source micropipettes (Xu et al., 2005), 
often analyze rapid (seconds to minutes) cellular responses to changes in applied gradients of 
chemoattractants such as cell polarization and intracellular gradient formation of molecules 
involved in migration (Sawano et al., 2002; Williams et al., 2003). Although these types of 
assays provide useful information regarding the underlying signaling mechanisms of cell 
polarization and migration, in vitro collective cell migration assays may be better indicators of 
actual cell behavior in vivo. 
In vitro collective cell migration assays, which are often monitored over hours or even 
days, create void areas in a monolayer of cells, which are then closed as cells migrate into the 
empty space. The in vitro scratch assay, which uses a pipette tip to scratch a cell monolayer and 
remove cells, is one of the most commonly used assays for this purpose (Liang et al., 2007). 
Because this approach kills cells, causing them to release unknown cytosolic factors into the 
surrounding medium (which can alter cell migration characteristics in an uncontrolled manner), 
and because this assay requires large numbers of cells and has limited reproducibility (Tavana et 
al., 2011), numerous other approaches that circumvent these problems have been developed: a 
circular invasion assay that removes cells with a rotating silicon tip (Kam et al., 2008), 
electroporation of a circular area of cells (Keese et al., 2004), mechanical stencil patterning 
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(Poujade et al., 2007), microfluidics patterning (Irimia and Toner, 2009) and laminar flow-based 
trypsin digestion (Murrell et al., 2011), and aqueous two-phase exclusion patterning (Tavana et 
al., 2011).  
Although many of these approaches are useful, they are generally performed on 
polystyrene dishes or glass slides, which have elastic moduli values in the megapascal and 
gigapascal range (Lee et al., 2004). However, the only in vivo organ that has this type of stiffness 
is bone (Rho et al., 1993), while other organs such as skin, brain, muscle and lungs have elastic 
moduli values in the low kilopascal range (Kaster et al., 2011; Liu and Tschumperlin, 2011; 
Diridollou et al., 2000; Engler et al., 2004). The need to perform wound healing assays extends 
from soft surfaces to other non-conventional culture platforms such as transwells, which are used 
to culture epithelial cells at an air-liquid interface (ALI) to achieve polarization, ciliation, 
differentiation, and formation of tight junctions that best mimic in vivo environments (Ross et al., 
2007; Dvorak et al., 2011; Wong et al., 2012); unfortunately, many of the aforementioned 
techniques cannot be incorporated into a transwell setup. 
To overcome these limitations, we developed an in vitro wound assay that utilizes an 
aqueous two-phase system (ATPS) of polyethylene glycol (PEG) and dextran (DEX). The assay 
is based on the following principles: aqueous PEG and DEX solutions remain immiscible due to 
polymer incompatibility; when droplets of the denser DEX phase are pipetted into a dish 
containing PEG solution, they sink to the bottom of the dish where they are held in place by 
surface tension forces between the two aqueous solutions and the substrate; and trypsin is 
enriched into the DEX phase where it locally digests cell-cell and cell-substrate interactions, 
which, upon washing, creates a small circular void into which cells around the periphery can 
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migrate. This method is applied to traditional cell culture dishes and transwells to demonstrate its 
ability to be applied to multiple cell culture substrates.  
4.2 Materials and Methods 
4.2.1 Identification of ATPS for Localized Trypsinization 
 ATPS solutions were formulated from PEG 35 kDa (81310, Sigma), DEX 500 kDa 
(DEXT500, Pharmacosmos), and sodium citrate (CIT) (C7254, Sigma). Polymers and salts were 
added to PBS and mixed overnight on a rocking stage to fully dissolve the reagents into solution. 
For solutions consisting of PEG, DEX, or CIT alone, solutions were enriched to 5, 10, 20, and 
30% w/w of individual reagents. For DEX+CIT, the 5% and 10% solutions consisted of 5% w/w 
and 10% w/w each of DEX and CIT in PBS, respectively. In a 96-well plate, 200 μl PEG 
solution was added to wells, followed by manual pipetting of 0.5 μl droplets of DEX or 
DEX+CIT solution. Wells were visualized with a Nikon ECLIPSE TE300 microscope over time 
to analyze droplet morphology and spreading. 
  
4.2.2 FITC-Casein Assay to Analyze Trypsin Activity and Partitioning 
A modified version of a previously described FITC-casein protocol was utilized to 
analyze trypsin activity and trypsin partitioning (Twining, 1984). First, assay performance was 
verified by testing PBS solutions with various pH values. FITC-casein (C2990, Molecular 
Probes) was reconstituted to 10 mg/ml in PBS and then further diluted to 2.5 mg/ml in PBS that 
was pH-adjusted with NaOH or HCl to values of 6, 7, 8, 8.5, and 9. Trypsin (T9935, Sigma) was 
reconstituted to 5 mg/ml in PBS with the same pH values as FITC-casein. In a 96-well U-bottom 
plate, 10 μl FITC-casein was added to 10 μl PBS and 5 μl trypsin solution (final trypsin 
concentration 1 mg/ml) (all with the same pH) (Figure 4.1 A). Wells were incubated for 0, 30, 
60, 180, 300, and 600 s, at which point the trypsin-FITC-casein reaction was neutralized by 
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adding 5% trichloroacetic acid (TCA) (BP555, Fisher) (Figure 4.1 B). Liquid was transferred 
from the 96-well plate to 200 μl tubes, which were centrifuged for 10 min at 9,300 rcf to pellet 
the unreacted FITC-casein (Figure 4.1 C). From the tubes, 60 μl supernatant was diluted 1:10 in 
pH-matched PBS and stored at 4 ˚C overnight; the following day, 60 μl of this solution was 
added to a 96-well plate, which was analyzed at excitation and emission wavelengths of 485 nm 
and 535 nm, respectively, on a Biotek Synergy Neo HTS Multi-Mode Microplate Reader (Figure 
4.1 D). 
Trypsin partitioning was analyzed in a similar fashion to the calibration outlined above, 
with slight modifications. First, baseline trypsin activity was determined for 5%, 10%, and 15% 
solutions of the following solutions: PEG, DEX, CIT, and DEX+CIT. All solutions were 
prepared in PBS and pH values were adjusted to 7 using NaOH or HCl. In a 96-well plate, 25 μl 
test solution was added to each well: 15 μl appropriate polymer solution containing 0.2 mg/ml 
trypsin and 10 μl FITC-casein. Wells were again incubated for 0, 30, 60, 180, 300, and 600 s, 
neutralized with 5% TCA; liquid was transferred to 200 μl tubes, centrifuged, and supernatant 
was diluted 1:10, which was then analyzed at excitation and emission wavelengths of 485 nm 
and 535 nm, respectively. Once baseline values were determined, ATPS trypsin partitioning was 
measured. First, the following ATPSs were prepared: 5% PEG/DEX, 10% PEG/DEX, 5% 
PEG/DEX+CIT, 10% PEG/DEX+CIT, 15% PEG/DEX+CIT (percent refers to the weight 
percentage of each polymer/salt in solution), each of which were enriched with 0.2 mg/ml trypsin 
(Figure 4.2 A). Solutions were thoroughly mixed and then allowed to equilibrate at room 
temperature for 30 min, followed by centrifugation for 10 min at 9,300 rcf (Figure 4.2 B). From 
the phase separated ATPSs, 15 μl was pipetted from each phase and added to a 96-well plate 
with 10 μl FITC-casein (Figure 4.2 C). The remaining steps including incubation, neutralization, 
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centrifugation (Figure 4.2 D), and acquisition of fluorescent readouts (Figure 4.2 E) were the 
same as above. 
 
4.2.3 Wound Closure by A549 Cells in Polystyrene Dishes and Transwell Inserts 
A549 cells were maintained in F12 medium supplemented with 10% FBS (12306C, 
Sigma) and 1% anti-anti (15240-062, Gibco) in a 5% CO2 37 ˚C incubator. Cells tested in 6-well 
polystyrene dishes were seeded at 20% confluence and grown to confluence over 5 days with 
medium changes every 48 h. Cells tested in 6-well transwell inserts were seeded at 2 different 
densities based on pre-wounding conditions. For cells maintained in submersion, cells were 
cultured in the same way as those in polystyrene dishes; however, for cells that were switched to 
ALI culture, cells were seeded at 75% confluence and grown to confluence over 2 days (Figure 
4.3 A), at which point media was aspirated from the apical chamber of the transwell and cells 
were maintained for a further 3 days at ALI (Figure 4.3 B). For ALI-cultured cells, media was 
changed every 48 h, and once cells were switched to ALI culture, apical chambers were washed 
daily with PBS. 
After 5 days of culture, wounding was performed by applying ATPS to localize trypsin to 
specific regions on the cell monolayer (Figure 4.3 C). First, wells were aspirated to remove 
media and then washed with PBS. Wells were then filled with 2 ml of solution consisting of PBS 
enriched with 10% w/w PEG 35 kDa and 10% v/v FBS; in the case of transwells, the basal 
chamber was filled with PBS. Next, 0.5 µl droplets of 10% w/w DEX 500 kDa enriched with 10 
mg/ml trypsin (85450C, Sigma) were dispensed in a 3x3 array into wells using a Matrix 
MultiChannel Equalizer Pipette (Thermo Scientific), at which point they were incubated in a 5% 
CO2 37 ˚C incubator to facilitate trypsin digestion. Upon removal from the incubator, 2 ml PBS 
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was vigorously added to each well to disrupt the ATPS and neutralize the localized reaction; this 
solution was quickly aspirated and 2 ml PBS was added back into each well and manually 
pipetted to facilitate the complete removal of cells from the locally digested areas (Figure 4.3 D). 
Wells were again aspirated to remove PBS, and for cells grown in polystyrene dishes, wells were 
either re-filled with growth medium or growth medium enriched with 50 ng/ml hepatocyte 
growth factor (HGF), while for cells grown in transwells, apical chambers were either re-filled 
with growth medium or maintained at ALI. Media were refreshed daily and wells maintained at 
ALI were rinsed every day with PBS. Subsequent cell proliferation and migration into the 
denuded areas were monitored over the course of 3 days (Figure 4.3 E). 
Statistical testing was performed using Origin Pro 8.5.1. Student’s t-tests were used to 
compare wound areas and wound closures; results were considered significant at p<0.05. 
 
4.3 Results and Discussion 
4.3.1 Identification of ATPS for Localized Trypsinization 
 To effectively create local wound areas in cell monolayers using ATPS, first it was 
necessary to identify a two-phase system that facilitated the formation of small localized droplet 
regions that retained their morphology over time. To this end, PEG/DEX, PEG/CIT, and 
PEG/DEX+CIT systems were tested at various concentrations. The PEG/CIT and 
PEG/DEX+CIT conditions were included based on a previously-published report that trypsin 
highly partitioned to CIT and maintained high activity in ATPSs with PEG formulations with 
molecular weights ranging from 0.6-8 kDa and CIT concentrations between 7 and 15.5% w/w 
(Tubío et al, 2007).  
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Although the previous report indicated high levels of trypsin activity and partitioning in a 
PEG/CIT system, the report utilized bulk solutions that did not require localized droplets to be 
patterned. Here, the CIT phase was denser than the PEG phase, which caused CIT droplets to 
sink to the surface of each well; however, after reaching the surface, CIT droplets lost their well-
defined dome-like morphology as they continued to spread across the surface of the well (Table 
1). As expected, all combinations of PEG/DEX resulted in well-defined formation of DEX 
droplets in the bottom of each well. Finally, 5% and 10% PEG/DEX+CIT solutions also formed 
and maintained droplets in wells, but their size was larger than the same weight percentage 
solutions of PEG/DEX. Based on these results, PEG/DEX and PEG/DEX+CIT solutions were 
further tested for trypsin activity and partitioning to achieve localize wounding.  
   
4.3.2 FITC-Casein Assay to Analyze Trypsin Activity and Partitioning 
A FITC-casein assay with PBS solutions with pH values of 6, 7, 8, 8.5, and 9 was used to 
verify the potential to use the assay in determining trypsin activity and partitioning. Trypsin has 
peak enzymatic activity at pH values between 7 and 9 (Bridson and Brecker, 1970), with the 
maximum occurring near a pH of 8.5 (Kasserra, 1969). The trypsin activity in the FITC-casein 
assay with different pH solutions follows this trend (Figure 4.4). As can be seen, trypsin 
incubated in pH 8.5 PBS produced the highest fluorescent signals over time, meaning that trypsin 
was the most enzymatically active and cleaved more FITC molecules from casein. At pHs of 7, 
8, and 9, trypsin activity was slightly lower, while trypsin activity at pH 6 was greatly decreased, 
likely due to conformational alterations that make the enzymatic site less accessible.   
 After verifying the utility of the assay in analyzing trypsin activity, it was applied to 
determine trypsin partitioning in various ATPSs. Normally partitioning is determined by taking 
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where K is the partition coefficient and Ctop and Cbottom are the concentrations of the biomolecule 
in the top and bottom phases, respectively. However, this measurement is generally obtained by 
directly measuring the biomolecule of interest. In the case of trypsin here, FITC is actually an 
indirect readout of trypsin concentration; the amount of FITC in solution is dependent on both 









where Ibottom and Itop are the FITC signal intensities from the bottom and top phases, respectively, 
and Abottom, and Atop  are the baseline trypsin activities of the enzyme in a single solution of that 
phase. Using the basic FITC-casein protocol (Figure 4.1), trypsin activity was analyzed for 5%, 
10%, and 15% solutions of PEG, DEX, CIT, and DEX+CIT (Figure 4.5 A). Trypsin incubated in 
PEG and DEX cleaves much less FITC (Figure 4.5 B), while trypsin in CIT or DEX+CIT 
releases much greater amounts of FITC into solution (Figure 4.5 C); this trypsin activity is 
quantified by finding the slopes of the linear fits to these data (Table 4.2).  
 The ATPS FITC-casein assay (Figure 4.2) produced similar plots of FITC vs. time 
compared to the basic FITC-casein assay (Figure 4.6 A). As can be seen from the magnified 
graphs of PEG and DEX ATPSs, fluorescent signals produced by PEG and DEX were still much 
lower than those produced from PBS (Figure 4.6 B). Interestingly, however, in the PEG and 
DEX+CIT systems, fluorescent signals produced by the PEG phase (green symbols) were 
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substantially higher than PBS (Figure 4.6 C), while their baseline values were much lower than 
PBS (Figure 4.5). This suggests that in this system trypsin actually partitions more to the PEG 
phase, which counteracts the low baseline trypsin activity to increase the signal. Fluorescent 
signal intensity (a function of trypsin partitioning and baseline activity in the polymer system of 
interest) was quantified by finding the slopes of the linear fits of these data (Table 4.3).  
By combining ratios of fluorescent signal intensities and baseline trypsin activities, as 
seen in the equation above, partition coefficients were calculated for PEG and DEX and PEG and 
DEX+CIT ATPSs (Table 4.4). K was approximately 1 for PEG and DEX systems, meaning 
trypsin equally partitions between phases and essentially distributes based on diffusion alone. 
Interestingly, it was confirmed that ATPSs of PEG and DEX+CIT resulted in strong partitioning 
of trypsin into the PEG phase (K>1). Because the goal is to localize trypsin to small droplets of 
DEX or DEX+CIT that can be used to locally digest cell-cell and cell-matrix interactions to 
create in vitro wounds, it is apparent that these ATPSs cannot be used for this purpose as 
formulated. Instead, by using a work-around approach and enriching the PEG phase with FBS, 
droplets of DEX enriched with trypsin can still be dispensed and maintained in a solution of 
PEG; in this format, the DEX droplets act as a point source of trypsin that locally digests cell 
attachments in the DEX droplet, and trypsin that diffuses out of the DEX phase is saturated by 
proteins in FBS, thereby preventing it from digesting cell-cell and cell-matrix interactions in the 
PEG phase. 
 
4.3.3 Wound Closure by A549 Cells in Polystyrene Dishes and Transwell Inserts 
Although trypsin activity was highest in CIT and DEX+CIT solutions, because CIT did 
not form localized droplets with PEG and because DEX+CIT and PEG ATPSs actually favored 
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partitioning to the PEG phase, a PEG+DEX ATPS with FBS was pursued to achieve localized 
wounding. Both 5% and 10% ATPSs were tested with 10 mg/ml trypsin in the DEX phase and 
10% FBS in the PEG phase, and both were able to produce wounds in a monolayer of cells 
(Figure 4.7). Figure 4.7 A shows representative images of cells exposed to a 10% ATPS; 
although 30 min is a reasonably long incubation time, it is clear that trypsin efficiently digests 
cell-cell and cell-matrix interactions during this time and that a series of gentle washes dislodges 
these cells to produce a clean wound area. The far right image is representative of a system in 
which FBS was not included in the PEG phase. In this case, due to the lack of trypsin 
partitioning and exclusion of FBS, trypsin digested cell-cell and cell-matrix interactions in the 
entire well and not just inside the DEX area. In terms of wound area, as expected, due to higher 
hydrophilicity and lower surface tension between the 5% DEX and PEG solutions, initial wound 
sizes were larger than their 10% counterparts (Figure 4.7 B). Because the wound areas were 
unreasonably large, and because the 5% ATPS produced more irregular (less circular) wound 
areas, the 10% ATPS was used for further testing.  
Interestingly, wound areas were significantly different for cells cultured on polystyrene 
dishes and those cultured on transwell inserts for DEX volumes of 0.5 µl (p=8.9x10-4) (Figure 
4.7 C). As can be seen, wound areas for cells cultured in 6-well inserts and exposed to 0.5 μl 
droplets of trypsin-enriched DEX were approximately 2.59 mm2, while wound areas for cells 
cultured on transwells were approximately 1.65 mm2 for the same DEX volume. To achieve 
similar initial wound areas so as to be able to compare wound closure in transwells and 6-well 
dishes, it was therefore necessary to dispense 0.7 µl DEX droplets into transwells, which had an 
average wound area of 2.55 mm2 and were therefore statistically similar to 0.5 µl droplets in 
polystyrene dishes (p=0.56). These results may be attributed to differences in cell morphology 
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caused by differences in cell-substrate binding and/or differences in cell surface (glyco)protein 
expression that modifies DEX interaction with the cell monolayer. However, at larger droplet 
volumes (1 and 2 µl), initial wound areas were not statistically different between polystyrene 
dishes and transwells (p=0.71, 1 µl; p=0.10, 2 µl). At larger volumes, the interactions between 
the polymer solutions are likely larger than interactions with the cell surface and therefore cause 
DEX droplets to spread equally across the cell monolayer and create similar wound areas. 
After initial wounding, cells proliferate and migrate into the denuded wound area over the 
course of 72 h (Figure 4.8 A). At 24, 48, and 72 h, wound areas were imaged and later 
normalized against their respective initial wound areas (Figure 4.8 B). As expected, cells 
cultured in polystyrene dishes and exposed to 50 ng/ml HGF (+HGF), a chemokinetic and 
mitogenic factor (To et al., 2002; Skouteris and Schröder, 1996), proliferated and migrated 
significantly more into the wound area compared to cells cultured in growth medium (Control) 
(p=4x10-8). Interestingly, all cells cultured on transwell inserts (Sub-Sub, Sub-ALI, ALI-Sub, 
ALI-ALI) closed their respective wound areas more significantly than cells cultured in 
polystyrene dishes (p=2.7x10-7 HGF vs. Sub-ALI; all other p<2.7x10-7). Even the cells that were 
cultured in submersion before wounding and returned to submersion culture after wounding 
(Sub-Sub), which is most like the conditions in the 6-well plate, closed their respective wound 
areas more rapidly than those in the 6-well plate (even when stimulated with HGF) (p=1.3x10-9 
vs. Control; p=1.8x10-9 vs. HGF). Furthermore, cells that were cultured at ALI throughout the 
entire experiment (ALI-ALI) exhibited more complete closure compared to other transwell 
conditions (p=0.0012 Sub-Sub vs. ALI-ALI; all other p<0.0012). There are several possible 
explanations for this observation. First, epithelial cells may undergo phenotypic changes due to 
culture at ALI that improve their migratory and proliferative capabilities. Second, returning cells 
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to ALI after wounding means there is an extremely thin layer of fluid over cells; as cells secrete 
molecules into the apical chamber they become much more concentrated than when cells are 
returned to submersion culture where they secrete factors into 1 ml or more of culture medium in 
the apical chamber. Chemokinetic and mitogenic molecules such as trefoil factor family peptides 
(Oertel et al., 2001) and epidermal growth factor family proteins (Crosby and Waters, 2010) 
would then be more accessible to cells and more likely to stimulate their migration and 
proliferation into the wound space.  
 
4.4 Conclusions 
Cell migration plays an important role in many physiological processes, and to better 
understand the cellular mechanisms that underlie cell migration, researchers have developed 
numerous in vitro wound assays that mimic these in vivo responses. Unfortunately, many of 
these assays are performed in unphysiologic environments, such as polystyrene dishes, thereby 
limiting the conclusions that can be drawn from assay results. Other assays require the use of 
specialized equipment and skilled operators to perform, which limits their potential adoptability 
into traditional biological research settings. ATPSs, on the other hand, only require rudimentary 
knowledge of how to prepare solutions and the ability to use pipettors and can therefore be easily 
adopted and scaled.  
A proof-of-concept for ATPS-based wounding was demonstrated with A549 cells 
cultured in polystyrene dishes and on transwell inserts. Transwells are important culture vessels 
in epithelial biology as they enable the differentiation of cells into functional and more 
physiologically relevant cell monolayers. Unfortunately, many traditional in vitro wounding 
techniques are not amenable to these types of cell culture dishes. Here, we used an ATPS of 
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trypsin-enriched DEX and FBS-enriched PEG to achieve efficient wounding of A549 cells 
cultured on transwells. Droplets of DEX applied to cells cultured in polystyrene dishes were 
larger than those dispensed onto cells cultured in transwells, suggesting that cell morphologies 
and/or cell surface protein expression may be different and cause differential spreading of DEX. 
Furthermore, after wounding, cells grown on transwells closed wound areas more rapidly than 
cells cultured in polystyrene dishes. Interestingly, cells exposed to ALI culture prior to wounding 
demonstrated faster wound closure compared to cells maintained in submersion culture, 
suggesting that culture at ALI may induce physiological changes that make cells more migratory 
and/or proliferative. 
To better understand cell behavior and better predict cell responses to external stimuli, it 
is important to develop next-generation tools and assays that are more physiologically relevant 
such as transwells and soft gels. This localized ATPS-based trypsinization not only satisfies this 
criterion, but it is also easily adopted into labs and can be easily scaled to high-throughput 
formats by interfacing the technique with automated liquid handlers and imaging systems. It will 
be important to further validate this technique by utilizing primary cells, such as small airway 
epithelial cells, and by investigating in vitro wounding on soft gels so as to better mimic 
wounding and cell migration in soft environments such as the lungs. In doing so, this next-
generation approach could be a potentially useful tool in better understanding cell migration and 
wound healing. Furthermore, as the technology is further validated and automated, one could 
envision this approach being a useful and informative tool in pre-clinical testing and high-







Figure 4.1: FITC-casein assay. A) A single solution of PBS or PBS with polymer is enriched 
with trypsin. A second solution of FITC-casein is added, mixed, and incubated for a prescribed 
amount of time. B) As time progresses, trypsin cleaves FITC from casein, thereby releasing it 
into solution. TCA is added to the solution to neutralize trypsin activity and stop the reaction. C) 
After centrifuging the reaction vials, unreacted FITC-casein is pelleted into the bottom of the 
vial, while FITC that was cleaved from casein remains soluble. D) An aliquot of solution 
containing solubilized FITC is diluted into another vial, which is read on a plate reader at 
excitation and emission wavelengths of 485 and 535 nm, respectively. The intensity of the 
fluorescent signal is proportional to the amount of FITC in solution, which is further dependent 










Figure 4.2: ATPS FITC-casein assay. A) In the ATPS FITC-casein assay, individual polymers 
and trypsin are first mixed together into a homogeneous solution. B) After centrifugation, the 
solution equilibrates into two distinct phases. Based on the physicochemical characteristics of the 
phase system and trypsin, trypsin may or may not partition to one phase over the other. C) 
Individual polymer solutions, which contain the partitioned trypsin, are separated into separate 
microcentrifuge tubes and each is further enriched with FITC-casein. As before, trypsin cleaves 
FITC from casein over time and releases it into solution; at the time point of interest, TCA is 
again added to neutralize the reaction (not shown). D) Centrifugation pellets the unreacted FITC-
casein, leaving the reacted and solubilized FITC in solution. E) As before, aliquots containing 
solubilized FITC are diluted into another vial, which are read on a plate reader at excitation and 
emission wavelengths of 485 and 535 nm, respectively. Similar to the basic FITC-casein assay, 
the intensity of the fluorescent signal is proportional to the amount of FITC in solution. Unlike 
the basic FITC-casein, however, the amount of FITC in solution is dependent on both the activity 






Figure 4.3: Schematic of ATPS-trypsin wound assay. A) Cells are seeded and maintained in 
submersion culture until they reach confluence. B) Upon reaching confluence, cells can be 
switched to ALI culture or maintained in submersion culture. C) After rinsing the dish with PBS, 
an ATPS of PEG and DEX is applied to locally digest cell-cell and cell-matrix interactions. In 
this case, the PEG phase is further enriched with FBS, while the DEX phase is enriched with 
trypsin. D) After incubating the ATPS to allow trypsin digestion, cell-cell and cell-matrix 
interactions are locally digested. By rinsing the chamber and pipetting PBS up and down several 
times, cells are released from the locally digested area, thereby leaving a denuded circular area. 
E) Cells can be further cultured in submersion or at ALI; over time, cells proliferate and migrate 






Figure 4.4: Trypsin activity in PBS with various pH values. Fluorescent signals from the 
FITC-casein assay for PBS solutions with pH values of 6, 7, 8, 8.5, and 9. The amount of 







Figure 4.5: Trypsin activity in different polymer solutions at pH 7. A) Fluorescent signals 
from the FITC-casein assay for 5%, 10%, and 15% solutions of PEG, DEX, CIT, and DEX+CIT. 
B) Magnified view showing only PEG, DEX, and PBS solutions. C) Magnified view showing 





Figure 4.6: Trypsin activity in various ATPSs. A) Fluorescent signals from the FITC-casein 
assay for 5%, and 10% ATPSs of PEG and DEX and 5%, 10% and 15% ATPSs of PEG and 
DEX+CIT. B) Magnified view showing only PEG and DEX ATPSs and PBS. C) Magnified 
view showing only PEG and DEX+CIT ATPSs and PBS. In the graphs, the letter in parentheses 
refers to the phase from which sample was taken from the ATPS; e.g., 5% P/D (P) refers to a 5% 






Figure 4.7: Initial wound characteristics of PEG and DEX ATPSs. A) Representative images 
of A549 cells cultured on transwell inserts and exposed to an ATPS of 10% PEG and DEX with 
10 mg/ml trypsin; left: cells immediately after application of the ATPS, middle left: after 30 min 
incubation, middle right: after 30 min incubation and washes to dislodge trypsinized cells, and 
right: after 30 min in which the ATPS did not have FBS. Scale bar: 1mm. B) Initial wound areas 
were calculated for 5% and 10% PEG and DEX ATPSs for 0.5, 1, and 2 μl droplets applied to 
A549 cells cultured in polystyrene dishes. C) Initial wound areas were also analyzed for 0.5, 0.7, 
1, and 2 μl droplets of DEX from a 10% PEG and DEX ATPS applied to A549 cells cultured on 
polystyrene dishes and transwell inserts. Wound areas were significantly different for 0.5 µl 
DEX droplets (p=8.9x10-4), while they were statistically similar for 1 (p=0.71) and 2 ul (p=0.10) 




Figure 4.8: Wound closure by A549s in polystyrene dishes and transwell inserts. A) 
Representative images of A549 cells cultured on transwell inserts and exposed to an ATPS of 
10% PEG and DEX in which the PEG was enriched with 10% FBS and DEX with 10 mg/ml 
trypsin; top left: cells immediately after application of the ATPS, top middle: after 30 min 
incubation, top right: after 30 min incubation and washes to dislodge trypsinized cells, bottom 
row: images taken at 24, 48, and 72 h time points. Scale bar: 1mm. B) Normalized wound areas 
of A549 cells over the course of 72 h: Control, F12 growth medium in a 6-well plate; +HGF, F12 
growth medium enriched with 50 ng/ml HGF in a 6-well plate; Sub-Sub, cells grown to 
confluence and maintained in submersion culture prior to wounding, then returned to submersion 
culture after wounding; Sub-ALI, cells grown to confluence and maintained in submersion 
culture prior to wounding, then switched to ALI culture after wounding; ALI-Sub, cells grown to 
confluence and maintained at ALI prior to wounding, then switched to submersion culture after 
wounding; ALI-ALI, cells grown to confluence and maintained at ALI prior to wounding, then 




Droplet Formation PEG/CIT PEG/DEX PEG/CIT+DEX 
5% N Y Y 
10% N Y Y 
20% N Y X 
30% N Y X 
Table 4.1: Droplet formation by various ATPS combinations. ATPS formulations that 
produce well-defined droplets that retain their shape over time are indicated by Y, while those 
that do not are indicated by N. Cells marked with X were not tested due to the incomplete 





A PEG DEX CIT DEX+CIT 
5% 3.696 2.384 48.085 33.855 
10% 2.570 2.448 21.128 26.599 
15% 1.730 2.053 11.957 10.897 
 
B PEG DEX CIT DEX+CIT 
5% 0.838 0.541 10.906 7.679 
10% 0.583 0.555 4.792 6.033 
15% 0.392 0.466 2.712 2.472 
Table 4.2: Trypsin activity in various polymer solutions. A) Slopes of the linear fits applied to 






A P/D (P) P/D (D) P/D+C (P) P/D+C (D+C) 
5% 0.837 0.514 1.303 1.556 
10% 0.478 0.504 2.187 3.688 
15%   1.825 3.081 
 
B P/D (P) P/D (D) P/D+C (P) P/D+C (D+C) 
5% 0.644 0.396 1.004 1.199 
10% 0.368 0.388 1.685 2.841 
15%   1.406 2.374 
Table 4.3: Slopes of linear fits to fluorescent signals for various ATPSs. A) Slopes of the 



















































Table 4.4: Trypsin partitioning in various ATPSs. Partition coefficients were determined for 
various ATPSs by dividing the ratios of fluorescent intensities (I), as determined in Table 4.3, 
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Aqueous-Two Phase Patterning of Detection Antibodies for 
Multiplexed and Crosstalk-Free ELISA 
This chapter describes the use of a PEG/DEX ATPS for patterning detection antibodies in a 
multiplexed and crosstalk-free enzyme-linked immunosorbent assay (ELISA). First, polymers 
were tested in several ELISA formats to verify their compatibility with ELISA. Next, PEG and 
DEX polymers were tested for antibody partitioning characteristics in various formats including 
timelapse immunofluorescence, spatially patterned antibody diffusion studies, and ATPS 
equilibration and dot blot. After verifying polymer compatibility with ELISA and antibody 
partitioning, PEG/DEX ATPS signal outputs were characterized for several polymer molecular 
weights and concentrations, blocking conditions, and spotting parameters. A 20% w/w 
PEG/DEX system with casein blocking was selected to achieve the highest fidelity signal output 
in an array-based planar immunoassay. A customized dimpled plate was developed in 
conjunction with the assay to facilitate manual patterning of antibody solutions and effective 
washing. Finally, samples of patients with graft-versus-host-disease (GVHD) were tested with 
the ATPS-ELISA; results show that ATPS-ELISA achieves better limits of detection, has 
broader linear dynamic range, has less background signal, and can be used to better stratify 






The enzyme-linked immunosorbent assay (ELISA) is used to accurately and reproducibly 
quantify levels of soluble proteins. The first ELISA that was developed involved the 
immobilization of proteins on an assay plate; these proteins were then detected by antibodies 
specific to an epitope on the protein of interest, and a signal was produced by way of an enzyme 
conjugated to a second antibody that created a chromogenic, fluorescent or chemiluminescent 
signal (Engvall and Perlman, 1971). This approach, now known as a direct ELISA, still exists 
today. Since this initial ELISA was developed, the technology has been modified to facilitate a 
greater range of functionality and applications. One common variation to the technique involves 
the immobilization of a capture antibody on the assay plate, known as a sandwich ELISA, which 
generally improves sensitivity and selectivity of the assay (Crowther, 2001). Owing to their 
versatility and reliability, ELISAs have been used to detect and/or diagnose a range of 
pathologies including HIV/AIDS (Halbert et al., 1986), malaria (Voller et al., 1975), cancer 
(Paul et al., 2005; Kim et al., 2002), and autoimmune diseases (Levine et al., 2012; Paczesny et 
al., 2010), among others. 
Due to their effectiveness, commercial ELISAs with standardized protocols are widely 
used in clinical, drug development, and biomedical research settings. ELISAs, however, are not 
without their limitations, such as high reagent costs, long assay incubation times, inefficient use 
of patient samples, and inability to prevent antibody cross-reactivity in multiplexed formats 
(Moody et al., 2002; Wiese et al., 2001). With increasing demand for greater amounts of data to 
aid in more complete patient stratification and diagnosis, as well as to explain patient response to 
therapeutic regimes, there has been a significant push to develop efficient multiplex platforms 
and assays. To this end, several multiplexed technologies have been developed that spatially 
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segregate capture antibodies to many individual spots or beads within an assay (MacBeath 2002; 
Ellington et al., 2009). These planar and bead-based technologies have been further developed by 
numerous companies into standardized and commercially available equipment that facilitate the 
multiplex detection of soluble proteins in ELISA format (Table 5.1). Although these methods 
can greatly increase ELISA throughput, they still often suffer problems associated with cross-
reactivity of detection antibodies applied as a cocktail. The interactions among detection 
antibodies or between detection antibodies and inappropriate capture antibodies or antigens can 
lead to false positive or false negative readouts.   
We eliminate the problem of cross-reactivity in multiplexed ELISA by using a PEG/DEX 
ATPS to confine detection antibodies to regions where their corresponding capture antibodies are 
immobilized on the surface of a polystyrene plate (Frampton et al., 2013). This method, referred 
to as ATPS-ELISA, works on the three following principles: (1) droplets of the denser DEX 
solution sink in the PEG solution and remain in contact with the assay plate during incubation; 
(2) interfacial tensions between DEX-PEG and DEX-assay plate cause the DEX droplets to form 
domes that remain in place; and (3) detection antibodies are retained, without diffusive 
dispersion, in the DEX phase due to partitioning effects. We combine the ATPS-ELISA 
technology with a customized polystyrene assay plate that helps further localize DEX droplets 
while also enabling efficient washing and signal detection. We demonstrate that this approach is 
effective at simultaneously detecting four different antigens associated with acute graft-versus-
host disease (GVHD), a disease that benefits from multiple biomarker analysis for definitive 
diagnosis and prognosis (Paczesny et al., 2009a). In addition to resolving the problem associated 
with antibody cross-reactivity in multiplexed ELISAs, our assay also consumes less antibody and 
patient sample than conventional single biomarker ELISA. These attributes, as well as the 
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potential for automation, make ATPS-ELISA a promising next-generation technique for clinical 
diagnostics and drug development by enabling better early-stage biomarker validation and later 
in clinical trials for improved patient stratification and to explain patient response to treatments. 
 
5.2 Materials and Methods 
5.2.1 PEG and DEX Polymer Compatibility with ELISA 
 In developing the ATPS-ELISA, it was first necessary to determine the compatibility of 
the different polymers with traditional ELISA workflow. To do so, a commercially available IL-
8 ELISA kit was tested (KAC1301, Life Technologies). This kit is a direct sandwich ELISA 
(Figure 5.1 A) that has the surfaces of 96-well plates pre-coated with capture antibodies directed 
against human IL-8, lyophilized human protein to be used as a protein standard, and prepared 
solutions of horseradish peroxidase (HRP)-conjugated detection antibodies and chromogen to 
produce signal. These types of pre-packaged kits decrease the amount of work required by the 
end user but can also decrease flexibility in tailoring the ELISA to suit each researcher’s needs. 
 First, three separate assays were performed side-by-side to determine the compatibility of 
PEG and DEX with the kit: (1) following manufacturer’s instructions with slight modifications 
for producing signal, (2) the same as (1) but also enriching each solution with DEX, and (3) the 
same as (1) but also enriching each solution with PEG. For example, in (2) when the assay calls 
for adding a solution of IL-8 antigen, instead of adding a pure solution of reconstituted protein, 
the IL-8 solution was enriched with DEX. Finally, whereas the manufacturer’s protocol called 
for the addition of tetramethylbenzidine to produce a colorimetric readout proportional to the 
amount of IL-8 in each well, the modified protocol used SuperSignal ELISA Femto Maximum 
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Sensitivity Substrate (PI37074, Fisher Scientific) to produce chemiluminescent signal, which 
was detected on x-ray film instead of on a plate reader. 
 Further tests to determine polymer compatibility were conducted with R&D Systems 
ELISA DuoSet kits (DY208, R&D Systems). Whereas the previous ELISA was a direct 
sandwich ELISA with pre-coated well plates, the DuoSet kit is an indirect sandwich ELISA 
(Figure 5.1 B) that provides all reagents in a lyophilized form; although this format generally 
requires more work by the end-user, it also enables greater flexibility in developing assays. 
Based on the incompatibility of the polymers with the direct sandwich ELISA, a series of 
experiments was performed to determine which step of the process was incompatible with the 
polymers. That is, by eliminating the polymer from only 1 step in each experiment, the reagent 
that was incompatible with the polymer-enriched version of the assay could be determined. 
 
5.2.2 Antibody Partitioning 
Antibody partitioning was determined with 3 separate methods: timelapse fluorescence, 
antibody co-localization analyses, and ATPS equilibration and dot blot. 
To perform timelapse microscopy, separate solutions of PBS were enriched with 20% 
w/w 500 kDa DEX (Dextran T500, Pharmacosmos) and 20% w/w 35 kDa PEG (81310, Sigma). 
Phycoerythrin-conjugated mouse anti-human CD184 IgG2a (555974, BD Pharmingen) and 500 
kDa fluorescein-dextran (D7136, Molecular Probes) were added to the stock solution of DEX at 
dilutions of 1:200 and 1:100, respectively. PEG was added to a 35 mm dish and 0.5 µl droplets 
of DEX were dispensed into the dish and imaged over the course of 2 h. 
Two separate antibody co-localization studies were performed. The first test analyzed the 
potential for cross-reactive antibodies to produce signal when spotted in proximity using ATPS. 
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First, a spot of mouse anti-ST2 and a spot of anti-goat antibody were placed within 1 mm 
proximity on a polystyrene dish and incubated at 4 ˚C overnight to allow antibody adsorption. 
Following blocking and ST2 antigen incubation, a DEX droplet containing biotinylated goat 
anti-ST2 was localized to the area where mouse anti-ST2 had been spotted and incubated for 2 h. 
Plates were then incubated with streptavidin-conjugated HRP (Strep-HRP) and signal was 
produced using chemiluminescent substrate. In the second test, mouse anti-TNFR was spotted 
onto a polystyrene dish as in the first test. After blocking and TNFR antigen incubation, a DEX 
droplet containing biotinylated goat anti-TNFR was spotted using ATPS so as to only partially 
overlap the capture antibody spot in a Venn diagram configuration. As in the first tests, plates 
were incubated with Strep-HRP and signal was developed with chemiluminescent substrate. In 
each test, images were acquired using a FluorChem M Digital Imager (ProteinSimple). 
ATPS equilibration and dot blot was performed by diluting biotinylated detection 
antibodies from ELISA kits (DY225, DY294, DY523, DY1747, R&D Systems) to 500 ng/ml in 
Eppendorf tubes containing 1 ml total 10% w/w PEG 35 kDa and 10% w/w DEX 500 kDa in 
PBS. Control tubes contained only PEG and DEX and were not enriched with antibodies. The 
contents of each Eppendorf tube were thoroughly mixed by rocking at room temperature for 10 
min. The tubes were then centrifuged at 400 rcf at 4° C for 15 min, which facilitated the 
complete phase separation and equilibration of the PEG and DEX phases. Polyvinylidene 
fluoride (PVDF) membranes (10413052, Whatman) were soaked in methanol for 15 s, water for 
2 min and finally PBS for 5 min. Six 0.5 µl samples each of the PEG and DEX phases were then 
dispensed onto the PVDF. The membranes were blocked in 1% BSA for 1 h and washed 4 times 
with PBS containing 0.05% Tween-20. Membranes were then incubated with streptavidin-
conjugated horseradish peroxidase for 1 h, washed 4 times, and incubated with SuperSignal 
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ELISA Femto Maximum Sensitivity Substrate. Chemiluminescent signal was detected using a 
FluorChem M Digital Imager. Partition coefficients, defined as the reagent concentration in the 
PEG phase divided by the reagent concentration in the DEX phase, were calculated by taking the 
ratios of chemiluminescent signals from the PEG and DEX spots on the PVDF membranes. 
 
5.2.3 ATPS-ELISA Characterization 
 Spatial control over ATPS-ELISA-based signal outputs was optimized for types of 
blocking conditions, molecular weights of polymers, and concentrations of polymers. For 
blocking conditions, bovine serum albumin (BSA) and casein buffers were tested at 
concentrations ranging from 0.1% to 5%. For polymer molecular weight, PEG was held constant 
at 35 kDa, while DEX molecular weights of 3.5, 10, and 500 kDa were investigated. Polymer 
concentrations of 5, 10, 20, and 30% were investigated for each of the combinations of PEG and 
DEX. 
 To test how each of the above parameters affected the size of the signal spot generated by 
the assay, a modified ATPS-ELISA was performed. Briefly, a polystyrene dish was coated with 
TNFR capture antibody at 4 ˚C overnight. Plates were washed and blocked for 1 h with the 
appropriate blocking buffer. Plates were washed again and then incubated with TNFR antigen for 
2 h. Following another wash, ATPSs with various combinations of polymer molecular weights 
and concentrations were used to dispense DEX droplets containing biotinylated TNFR detection 
antibody into PEG and incubated for 2 h. Next, plates were washed, incubated for 1 h with Strep-
HRP, washed, and finally incubated with chemiluminescent substrate to generate signal, which 




5.2.4 Customized Dimpled Plate 
 A mold for the production of a customized dimpled-well plate was designed in AutoCAD 
(AutoDesk) and SolidWorks (Dassault Systems), which was then machined from aluminum at 
Protomatic, Inc. (Dexter, MI). Using the aluminum mold, plates were hot embossed from square 
polystyrene dishes by melting the plates above their glass transition temperature and then 
inducing an abrupt temperature change to harden the dishes and release them from the aluminum 
mold. 
 
5.2.5 Multiplexed and Crosstalk Free Detection of 4 Biomarkers from Patient Samples 
 Standard curves for four GVHD biomarkers (HGF, elafin, ST2, and TNFR1) were 
generated in multiplexed ATPS-ELISA format in the customized dimpled plate by modifying the 
singleplex ELISA workflows for their corresponding commercially available kits (DY225, 
TNFR; DY294, HGF, DY523, ST2; and DY1747, elafin, R&D Systems). Briefly, monoclonal 
capture antibodies were reconstituted in PBS to their recommended concentrations and 3 µl of 
each was dispensed into one of the small dimples in the customized plate. Plates were incubated 
at 4 ˚C overnight in dishes containing saturated KimWipes to prevent evaporation of the 
droplets. After overnight incubation, plates were washed (all wash buffer contains PBS with 
0.05% Tween20) 5 times and then blocked for 1 h with 3% casein in PBS. During blocking, 
multiplex antigen ladders were prepared by mixing single antigens into a common standard 
diluent of 10% healthy pooled plasma and 1% FBS in PBS to maximum concentrations of 
10,000 pg/ml for each antigen. A quarter-log serial dilution was then performed to obtain 
concentrations ranging from 1.78 pg/ml-10,000 pg/ml. After blocking, plates were again washed 
5 times and antigen solutions were added to the appropriate larger common wells of the 
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customized plate and incubated for 2 h. Following another 5 washes, ATPS (10 µl 20% w/w 
PEG 35 kDa containing 0.1% casein added to each well) was used to spot DEX droplets (3 µl, 
20% w/w DEX 500 kDa) containing the appropriate detection antibody to the same dimple 
containing its corresponding capture antibody and incubated for 2 h. Next, plates were washed 8 
times to thoroughly remove polymer, incubated for 1 h with Strep-HRP, washed 5 times, and 
finally incubated with chemiluminescent substrate to generate signal, which was detected using a 
FluorChem M Digital Imager. 
 Heparinized plasma samples were also collected from patients who received allogeneic 
bone marrow transplantation at the University of Michigan between 2000 and 2010 for testing. 
Plasma samples were collected under protocols approved by the University of Michigan 
Institutional Review Board and stored at the University of Michigan. This group, which 
contained samples from patients that received allogeneic bone marrow transplants and did not 
manifest symptoms of GVHD, as well as patients that received allogeneic bone marrow 
transplants and were diagnosed with acute GVHD, was compared with healthy controls. The 
workflow for performing ATPS-ELISA of patient samples was the same as outlined above, 
except the test solution applied to each well contained 10% patient plasma and 1% FBS in PBS. 
We were blind to the GVHD status of the samples during the experiment and image 
quantification. 
All plots and statistical analyses were carried out in Sigmaplot with Sigmastat (Systat 
Software).  Standard curves were fit using a four parameter logistic function. The limit of 
detection (LoD) was determined from the equation LoD = LoB + 1.645*(SDlow concentration sample), 
where SD is the standard deviation and LoB is the limit of blank.  LoB was calculated from LoB 
= meanblank + 1.645*(SDblank) (Armbruster and Pry, 2008).  Linear dynamic range (LDR) was 
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determined using LDR = maximum linear response/ LoD. To compare ATPS-ELISA values with 
conventional ELISA values, a Pearson product-moment correlation test was used. 
 
5.3 Results and Discussion 
5.3.1 PEG and DEX Polymer Compatibility with ELISA 
 Using a direct sandwich ELISA format (Figure 5.1 A), we found that PEG and DEX were 
both incompatible with at least a portion of the ELISA (Figure 5.2). In this figure, X-ray film 
was exposed to chemiluminescent signal that was produced from individual wells in a 96-well 
plate. Signal intensity, i.e., the density of the black region, is proportional to the amount of 
antigen that was present in the individual wells; therefore, signal intensity should be greatest in 
the top well where the concentration of IL-8 was highest (200 pg/ml), decrease by ½ in each 
subsequent well due to the serial dilution of IL-8, and be 0 in the bottom well, where wells were 
left unexposed to IL-8.When following the prescribed instructions from the manufacturer’s 
protocol (with the aforementioned modifications to the signal generation step), we obtained the 
expected results (Figure 5.2 #1). However, when PEG (Figure 5.2 #2) or DEX (Figure 5.2 #3) 
were added to the ELISA, signal intensity was not only much higher than expected, but in the 
case of PEG the signal was uniform across conditions and in the case of DEX the level of 
background staining was exceptionally high (as demonstrated by the large amount of signal in 
the bottom well, where no signal should be present). 
 Due to these results, we switched to an indirect sandwich ELISA kit because all reagents 
are provided in a lyophilized format. This format gives us more control over each step and 
allows us to use known solutions instead of pre-packaged reagent solutions that contain an 
unknown mixture of preservatives, dyes, and other reagents. Using the indirect sandwich ELISA, 
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we performed a series of experiments in which PEG and DEX were omitted from just one step of 
the assay. In doing so, we determined that incubation of PEG and DEX with an HRP-conjugated 
reagent led to non-specific binding that produces signals seen in Figure 5.2 #2-3. By omitting 
PEG and DEX from the step that includes HRP, we again obtain the expected results (Figure 5.2 
#5). This is an important result in the development of the assay because the end goal is to 
develop technology in which detection antibodies can be spatially patterned. Many commercially 
available kits have detection antibodies that are directly conjugated to HRP; as can be seen from 
our results, however, we cannot use these HRP-conjugated antibodies because they will 
nonspecifically bind and produce signal that is not proportional to the amount of protein in 
solution, thereby yielding false positive readouts. Therefore, indirect sandwich ELISA workflow, 
where detection antibodies are either unconjugated or biotinylated, must be used and another 
enzyme-conjugated antibody must be applied in bath solution without PEG or DEX to generate 
the appropriate signals. 
  
5.3.2 Antibody Partitioning 
 After demonstrating that PEG and DEX are compatible with indirect sandwich ELISAs 
as long as they are not applied with HRP, and keeping in mind the end goal of creating a 
multiplexed ELISA that eliminates antibody crossreactivity by patterning detection antibodies, 
we sought to demonstrate that antibodies partition to the DEX phase in an ATPS. 
 First, timelapse microscopy was used to visualize DEX droplet stability and antibody 
diffusion characteristics when dispensed into a solution of PEG. As can be seen in Figure 5.3, the 
DEX droplet, which is visualized using FITC-DEX, initially forms a circular cross-sectional area 
that slightly decreases in size over 2 h but is still stable and distinct from the surrounding PEG 
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phase. Furthermore, PE-IgG is colocalized to the same region as DEX and does not show 
diminishing signal intensity, suggesting that antibodies stably partition to the DEX phase. 
 Although timelapse microscopy suggests that antibodies partition to DEX, there is a 
possibility that antibodies diffuse out of the DEX droplet and the signal is not sufficiently 
detected by microscopy. To this end, we performed 2 antibody co-localization experiments. In 
the first, a mouse anti-ST2 capture antibody was spotted within 1 mm of an anti-goat antibody 
(Figure 5.4 A). After blocking and incubating with ST2 antigen, ATPS was used to spot 
biotinylated goat anti-ST2 detection antibody on top of the capture antibody area (Figure 5.4 B) 
and incubated for 2 h. Plates were then washed, incubated with Strep-HRP, washed and 
developed using chemiluminescent substrate. If detection antibodies stay retained within the 
DEX droplet, signal will only be localized to the ST2 signal area; however, if detection 
antibodies diffuse away from the droplet, the anti-goat antibody will react with the goat-derived 
detection antibody and produce a second signal spot (Figure 5.4 C). As can be seen from the 
readout (Figure 5.4 D), antibodies were retained and signal was localized to a single spot. 
 The second antibody co-localization experiment was a further verification of the results 
of the previous assay. After spotting TNFR capture antibody (Figure 5.5 A), blocking and 
incubating with antigen, ATPS was used to partially overlap a spot of detection antibody to the 
initial capture antibody area (Figure 5.5 B). Following the same washing and chemiluminescent 
development steps, signal was only produced in the overlapping region, much like a Venn 
diagram (Figure 5.5 C). 
 Finally, ATPS equilibration and dot blot was used to quantify antibody partitioning. After 
thoroughly mixing solutions of PEG and DEX enriched with biotinylated detection antibodies, 
solutions were equilibrated into two distinct phases (Figure 5.6 A). During this process, 
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antibodies naturally partition based on molecular characteristics and phase system properties. We 
sampled aliquots from each phase and detected chemiluminescent signals from the aliquots on a 
FluorChem M Digital Imager. In this format, chemiluminescent signal intensity is proportional to 
the amount of antibody in solution. By dividing signal intensity of the PEG phase by that of the 
DEX phase, we obtained partition coefficients for several different ATPS concentrations (Figure 
5.6 B). As can be seen, partition coefficients were < 0.45 for all antibodies in the phase system 
tested; for elafin, this means there is approximately a 2:1 ratio of antibodies in the DEX:PEG 
phases, and that in all other phases the ratio is higher. Although this number is high for 
partitioning, when analyzed in combination with other partition results, it seems that antibodies 
do strongly partition. Unfavorable partition coefficients found by dot blot are likely due to high 
background and/or low signal intensity. This low signal-to-noise ratio would lead to the 
calculation of larger partition coefficients, even when signal is visually predominantly produced 
from the DEX phase.  
 
5.3.3 ATPS-ELISA Characterization 
 After demonstrating ATPS compatibility with ELISA and effective antibody partitioning, 
we characterized the signals generated by various combinations of ATPS molecular weights and 
concentrations as well as blocking schemes. To do so, we modified the conventional ELISA 
(Figure 5.7 A); instead of bath applying detection antibodies, we used ATPS to manually pipette 
detection antibodies into small localized regions on a plate uniformly coated with capture 
antibodies. Using this approach, the signal that was generated was proportional to the area over 
which the DEX droplet containing the detection antibody was applied.  
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When considering blocking conditions, casein tended to outperform BSA (Figure 5.7 B). 
As can be seen, when analyzing the signals generated by various concentrations of 500 kDa DEX 
ATPSs, there seems to be a higher degree of background staining when BSA is used. Although 
this staining could result from insufficient washing, BSA also tends to form phase systems with 
PEG and DEX and could therefore interfere with the localization of detection antibodies. We 
also evaluated the effects of polymer molecular weights and concentrations (Figure 5.7 C). As 
expected, signal areas were smaller for higher molecular weights and higher concentrations of 
polymers due to higher surface tensions between the phases that minimized the amount of 
droplet spreading on the surface. 
Because the end goal is to optimize an ATPS that can be utilized for multiplex ELISA, it 
is necessary to be able to create multiple small signal areas in a single well of a multi-well plate. 
Casein, which demonstrated cleaner signals with less background staining, was therefore 
selected as the blocking buffer for future experiments. When selecting concentrations and 
molecular weights of polymers to achieve small signal areas, we had more flexibility. As can be 
seen in Figure 5.7 C, signal area decreases for higher concentrations of all polymer molecular 
weights, and in the case of BSA, signal area is approximately the same for ATPSs with 20% w/w 
DEX 500 kDa, 25% w/w DEX 40 kDa, and 30% DEX 10 kDa. However, at these very high 
concentrations, solutions become exceedingly viscous and difficult to handle. Therefore, the 20% 
w/w DEX 500 kDa/PEG 35 kDa ATPS was chosen because its signal areas were small enough to 
enable 4-plex ELISA in a well the size of a 96-well plate and because it had sufficiently low 




5.3.4 Customized Dimpled Plate 
 Although 96-well plates are common laboratory supplies and can be used with automated 
equipment, they are more difficult to use with the ATPS-ELISA format because their high walls 
make it difficult to thoroughly wash and remove the ATPS solutions. To facilitate easier washing 
and manual pipetting and localization of antibodies, several iterations of customized plates were 
designed and tested. One approach utilized wax pencils to “draw” hydrophobic well walls on a 
planar surface and a second approach used a xurographer to cut circular holes into tape, which 
was then stuck to a polystyrene dish so that the holes acted as sample wells. 
 These first attempts, although capable of creating multiple wells on a single planar 
surface, were not robust. For example, wax often detached from the surface, thereby removing 
all “wells” from the surface; furthermore, if the tape stencil was not applied perfectly to the 
polystyrene dish, liquid from individual wells would seep underneath the tape and mix with 
adjacent wells. Due to these problems, and because we sought to facilitate easier manual co-
localization of capture and detection antibody spots, we designed a new customized plate in 
AutoCAD and SolidWorks (Figure 5.8). The negative of the plate shown in Figure 5.8 A was 
machined from aluminum at Protomatic, Inc. and was used as a mold with which to hot emboss 
square polystyrene dishes. A magnified view (Figure 5.8 B) shows the distinct features of the 
plate that optimize its use for ATPS-ELISA. First, a 9x9 array of 6.5 mm diameter wells are used 
for incubating samples. Second, 4 1.5 mm diameter dimples (colored green, red, blue, and 
purple) are included in each larger well, which are used as sub-wells for 4 different capture and 
detection antibody pairs. These small dimples, in addition to helping to localize DEX, also act as 
a physical feedback that help guide manual pipetting. Finally, the shallow well and dimple 
features facilitate rapid and thorough washing of the plate. The resulting plate after hot 
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embossing is shown in Figure 5.8 C; although the exterior plate walls are not retained in the final 
plate, they do not actually play a role in the assay workflow and their absence does not affect its 
performance. 
 
5.3.5 Multiplexed and Crosstalk Free Detection of 4 Biomarkers from Patient Samples 
 Using the customized plates, the following 4 biomarkers were detected in multiplex 
ATPS-ELISA format in standard diluent: elafin, HGF, ST2, and TNFR (Figure 5.9 A). As can be 
seen, although each protein was spiked into standard diluent at the same concentrations in each 
well, their corresponding signals displayed different characteristics (Figure 5.9 B). Using the 
signals produced from each antigen at concentrations ranging from 0-10,000 pg/ml, standard 
curves were generated for each biomarker (Figure 5.9 C-F). As can be seen, the single and 
ATPS-ELISA formats produced standard curves with similar sigmoidal shapes. However, by 
inspecting the graphs and by calculating LoD and LoB for each biomarker, it is apparent that 
ATPS-ELISA tends to outperform single standard ELISA. For elafin, HGF, and ST2, ATPS-
ELISA has lower LoD, meaning protein can be detected and quantified at lower concentrations, 
and higher LDR, meaning there is a broader range of protein concentrations that can be 
quantified. Although traditional ELISA outperformed ATPS-ELISA for TNFR, the LoD and 
LDR were very similar between the two formats. 
Next, we used traditional single ELISA and ATPS-ELISA to analyze plasma samples 
from three patient groups: healthy controls (n=20), allogeneic bone marrow transplant patients 
who did not manifest symptoms of GVHD (GVHD –; n=19, median 28 days post-transplant) and 
allogeneic bone marrow transplant patients who had been diagnosed with acute GVHD 
(GVHD+; n=32, median 28 days post-transplant) (Figures 5.10-5.11). ATPS-ELISA was well-
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correlated with individual sandwich ELISAs by Pearson product-moment correlation, 
demonstrating the robustness of this technique (Figure 5.12). As expected, the GVHD+ patient 
group had higher levels of HGF, elafin, ST2 and TNFR1 than the GVHD– group and the healthy 
donor group. Furthermore, owing at least partially to the lower LoD and greater LDR in 
multiplexed ATPS-ELISA compared to traditional single ELISA, we were able to more 
effectively assess the GVHD status of the samples. These observations are consistent with 
observations from others that suggested that small spot sizes and assay volumes produce superior 
LoD and LDR values (Ekins, 1989; Hartmann et al., 2009). It is also possible that ATPS-ELISA 
benefits from microscale surface localization effects that enhance detection antibody binding, 
more effective washing due to the shallow well profiles, and less depletion of chemiluminescent 
substrate, all of which can affect LoD and LDR. Finally, receiver operating characteristic (ROC) 
analysis indicated that our test was sensitive and specific, as determined by measuring the area 
under the ROC curve (Figure 5.13).  
 
5.4 Conclusions 
In our assay, capture antibody spots can be arranged in a variety of plate formats similar 
to other array-based multiplexed ELISAs. Importantly, the resulting assay signals can be read 
with a range of plate readers and chemiluminescence imagers, making it easy to adopt and scale. 
We demonstrated that the ATPS-ELISA method works with proteins contained in buffered 
solutions as well as with human plasma. Our assay offers several advantages over conventional 
single biomarker ELISAs including use of small plasma volumes (≤1 µL/well of plasma for four 
biomarkers), cost savings (orders of magnitude less detection antibody consumption) and use of 
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conventional plate materials and detection systems. Most importantly, it eliminates antibody 
cross-reactivity in the multiplexed format.  
While many biomarkers have been discovered, there are multiple barriers (especially for 
multiplexed biomarker assays) to biomarker verification, qualification and FDA approval. One 
technological barrier has been the lack of multiplexed immunoassays that are efficient in usage 
of precious samples (consume less per run), robust in providing quantitative data without an 
increase of background or cross-reactivity, rapidly customizable and free from reliance on 
difficult to access reagents, plates and hardware (HTStec 2010; Master et al., 2006). In addition, 
poor antibody specificity is problematic for immunoassays in general. Even with the best 
antibodies, high background and loss of linearity occur with multiplexing due to higher total 
antibody concentrations. Our assay addresses these key areas and removes a bottleneck to 
clinical translation by utilizing a customized dimpled plate to localize (and therefore eliminate 
cross-reactivity) capture and detection antibody droplets as well as consuming small amounts of 
patient samples. Because antibody pairs are co-localized to small defined areas, our multiplexed 
signals are cleaner due to lack of cross-reactivity. This also aids in the multiplex validation 
procedure because each biomarker in the multiplex panel is independent of the others. Therefore, 
if reagents change or one assay does not work, the remaining biomarkers are still valid. This 
reduces time and cost associated with development and validation of new panels of multiplexed 
immunoassays.  
In addition, a single biomarker is often not sufficient for conclusive diagnosis, patient 
stratification, or definitive explanation of patient response to drugs. In the context of GVHD 
diagnosis and biomarker qualification, for example, it is important to use a panel of multiple 
biomarkers (Paczesny et al., 2009a). Once diagnosed with GVHD, patients are usually 
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administered immunosuppressant drugs such as corticosteroids, or in the case of corticosteroid-
resistant GVHD, patients are given anti-IL2Rα, anti-TNFR1 or anti-thymoglobulin therapy 
(Paczesny et al., 2009b). These drugs are effective at controlling the T-cell mediated immune 
response associated with GVHD, but they may cause serious side effects. In addition, 
suppression of the immune response, which is required for GVHD treatment, may increase the 
risk of cancer relapse and serious infections. To highlight the importance in our study, one of the 
GVHD– patients had high levels of HGF (6615 pg/mL), as well as slightly elevated levels of 
TNFR1 (990 pg/mL). Based only on the levels of these two biomarkers, this patient could have 
been diagnosed with GVHD and could have potentially received unnecessary treatment. 
However, with the inclusion of ST2 and elafin measurements that were both below the limit of 
detection, this patient can be considered GVHD– and avoid unnecessary treatments that may 
cause dangerous side effects. This issue is further underscored by the fact that overall GVHD 
patient cohort survival rate does not always improve, even after "successful" diagnosis and 
treatment. This indicates that some patients may be stratified based on incomplete biomarker 
data, which leads to inappropriate treatment with immunosuppressant drugs and further 
complications and mortality. In the context of drug development, in clinical trials it would be 
more useful to analyze levels of multiple biomarkers to more fully understand patient responses 
(both on-target and off-target) and to use the information to optimize dosages and/or delivery 
characteristics. In either case, however, the only way to confidently make decisions based on 
multiplex assays is to use tests with very low probabilities of false positive signals, which is 
effectively achieved in our assay.  
Because our method is simple and requires few (if any) fabrication steps or customized 
materials, we expect that it is more easily translatable into clinical, research, and drug 
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development settings than other multiplexing technologies. The multiplexing capabilities offered 
by this assay, in addition to the minimal potential for false positive signals, make this assay a 
potentially exciting tool to aid in biomarker analysis to better explain patient responses to 
therapeutic regimes and optimize treatment protocols. 




Figure 5.1: Direct and indirect sandwich ELISA formats. A) In the direct sandwich ELISA, 
capture antibodies are bound to the surface (i). After washing away excess capture antibody in 
solution, plates are blocked (ii) and then incubated with test solution. Capture antibodies bind to 
specific antigens from the test solution (iii). Following another wash, wells are incubated with 
detection antibodies, which are directly conjugated to signal-generating enzymes such as 
horseradish peroxidase (iv). Following another wash, a final solution is added that contains a 
substrate that reacts with the enzyme to produce a colorimetric, fluorescent, or chemiluminescent 
signal (v). B) In the indirect sandwich ELISA, the format is very similar (i-iii), except the 
detection antibody is either unlabeled or biotinylated (iv). An additional incubation is required 
where an enzyme-conjugated molecule is added; this molecule is generally either an antibody 
directed against the species of the corresponding detection antibody or conjugated to streptavidin 
(v). The final step also requires incubation of a solution containing substrate that reacts with the 
enzyme on the signal-producing molecule to produce a colorimetric, fluorescent, or 





Figure 5.2: X-ray film readouts of an IL-8 ELISA to test PEG and DEX compatibility. 1) 
Results from the standard direct ELISA protocol where the only step in the protocol that was 
changed was switching the enzyme substrate from a colorimetric substrate to a chemiluminescent 
substrate. 2) Results from the same protocol used in (1) except all solutions were enriched with 
PEG. 3) Results from the same protocol used in (1) except all solutions were enriched with DEX. 
5) Results from a standard indirect ELISA protocol in which PEG was added to the solutions for 
all steps except the addition of Strep-HRP; the HRP is precipitated onto the surface by both 






Figure 5.3: Fluorescent timelapse of a DEX droplet containing fluorescently-labeled 
antibody. A 20% w/w solution of DEX 500 kDa was enriched with a 1:100 dilution of FITC-
DEX 500 kDa and 1:200 dilution of phycoerythrin-conjugated antibody. After initially 
dispensing the droplet into a solution of 20% PEG 35 kDa (left), the droplet slightly spreads on 
the surface. Over the course of 30 (middle) and 120 min (right), the droplet slightly shrinks in 
size but it is clear that antibody is retained within the droplet as shown by the overlap of 






Figure 5.4: Co-localization study of cross-reacting antibodies. A) Mouse anti-ST2 and anti-
goat antibodies were spotted within 1 mm of each other. Plates were then washed to remove 
unbound antibodies, blocked, and incubated with ST2, which was bound by the capture 
antibodies. B) Following another wash to remove unbound antigen, ATPS was used to dispense a 
DEX droplet containing biotinylated goat anti-ST2 to the same area as its capture antibody. C) If 
the detection antibodies are retained within the DEX droplet, subsequent incubation with Strep-
HRP and chemiluminescent developer will only produce signal where the detection antibody was 
spotted (left). If, however, antibodies do not partition to the DEX droplet, they will diffuse 
outward and will be bound by the anti-goat antibodies located adjacently (right). D) Results 
show that chemiluminescent signal is indeed only produced in the location where both capture 






Figure 5.5: Co-localization of antibodies in a Venn diagram configuration. A) Mouse anti-
TNFR antibodies were localized to a small region on a dish. B) Following washing, blocking, 
and incubation with TNFR antigen, ATPS was used to spot a DEX droplet containing 
biotinylated goat anti-TNFR so that only a small portion of the DEX droplet overlapped the 
capture antibody region. C) Assuming detection antibodies are retained within the DEX phase, 
subsequent incubation with Strep-HRP and chemiluminescent substrate should only produce 
signal in the overlapping region of the Venn diagram. Results show that signal is indeed only 







Figure 5.6: ATPS equilibration and quantification of antibody partitioning. A) Solutions of 
PEG and DEX were enriched with fluorescently-labeled antibodies. Microcentrifuge tubes were 
thoroughly mixed and then allowed to naturally phase separate over the course of 2 h. Following 
phase separation (and natural partitioning of antibodies), aliquots were removed from each phase 
and fluorescent signals were detected using a plate reader. B) Partition coefficients were 
calculated by dividing fluorescent signal intensity of the PEG phase by fluorescent intensity of 






Figure 5.7: ATPS-ELISA signal characterization. A) In traditional ELISA, the entire surface 
of a polystyrene well is coated with capture antibody that binds antigen; a bath solution of 
detection antibodies is then applied, which also binds antigen across the entire surface. 
Therefore, when Strep-HRP and chemiluminescent substrate are added, signal is produced in the 
entire well. To characterize signal spot size in ATPS-ELISA, the entire surface of a polystyrene 
well is coated with capture antibody that binds antigen; ATPS localizes detection antibodies in 
drops of DEX. Therefore, when Strep-HRP and chemiluminescent substrate are added, signal is 
produced in small discrete areas. B) BSA and casein blocking conditions were tested in ATPS-
ELISA; representative images from 500 kDa DEX show that casein blocked more effectively 
than BSA and had less background signal. C) Signal area size was characterized for various 




Figure 5.8: Customized ATPS-ELISA plate. A) SolidWorks representation of the final version 
of the customized plate; the negative of the plate was machined into aluminum to act as a mold 
with which to emboss a polystyrene dish. B) Magnified view of the plate; the plate contains a 
9x9 array of larger 6.5 mm wells for incubating samples. The 4 smaller dimples in each larger 
well (falsely colored to highlight the ability to localize 4 different antibody pairs) are used to 
localize capture and detection antibodies and to provide physical feedback for manual pipetting. 
Wells and dimples have shallow well features that facilitate washing. C) Example of a final 





Fig. 5.9: Standard curves for ELISA and ATPS-ELISA. A) Close up view of the customized 
plate with false color added to show the areas where the various biomarkers were detected (red, 
HGF; cyan, elafin; blue, ST2; green, TNFR). B) Representative images of a multiplexed readout 
from ATPS-ELISA for various concentrations of elafin, HGF, ST2, and TNFR. C) Single ELISA 
and ATPS-ELISA standard curves for HGF. D) Single ELISA and ATPS-ELISA standard curves 
for elafin. E) Single ELISA and ATPS-ELISA standard curves for ST2. F) Single ELISA and 
ATPS-ELISA standard curves for TNFR. Curves for all four GVHD biomarkers were generated 
by densitometric quantification of chemiluminescence images.  Error bars represent standard 





Figure 5.10: Patient levels of biomarkers for GVHD using single ELISAs. A) Quantification 
of levels of HGF. B) Quantification of levels of elafin. C) Quantification of levels of ST2. D) 
Quantification of levels of TNFR. Levels were determined by comparing densitometric signal 
intensity of patient samples to their respective standard curves. Significance between the 
GVHD+ group and the GVHD- and healthy control groups was obtained for HGF and TNFR1 
(p<0.05 by one-way ANOVA with Dunn’s multiple comparison test), but not for elafin or ST2, 
although ST2 values for the GVHD+ group tended to be higher than the other groups. Error bars 






Figure 5.11: Patient levels of biomarkers for GVHD using ATPS-ELISAs. A) Quantification 
of levels of HGF. B) Quantification of levels of elafin. C) Quantification of levels of ST2. D) 
Quantification of levels of TNFR. Levels were determined by comparing densitometric signal 
intensity of patient samples to their respective standard curves. Significance between the 
GVHD+ group and the GVHD- and healthy control groups was obtained for HGF and TNFR1 
(p<0.05 by one-way ANOVA with Dunn’s multiple comparison test), but not for elafin or ST2, 
although ST2 values for the GVHD+ group tended to be higher than the other groups. Error bars 






Figure 5.12: Pearson correlation of single ELISA and ATPS-ELISA. A) Scatter plot showing 
correlation between patient sample measurements for ATPS-ELISA (x-axis) and single sandwich 
ELISA (y-axis) for HGF. B) Scatter plot showing correlation between patient sample 
measurements for ATPS-ELISA and single ELISA for elafin. C) Scatter plot showing correlation 
between patient sample measurements for ATPS-ELISA and single ELISA for ST2. D) Scatter 
plot showing correlation between patient sample measurements for ATPS-ELISA and single 







Fig. 5.13. ROC curves for standard single ELISA and ATPS-ELISA. A) ROC curves for 
multiplexed ATPS-ELISA. The nearly right angle feature, and therefore the high areas under the 
ROC curves (maximum possible area of 1), show that ATPS-ELISA is highly specific and 
sensitive. B) ROC curves for standard single ELISA. ROC curves with lower areas under their 






Company and Platform Type of ELISA (Planar 
array or bead-based) 
Publicized maximum 
degree of plexing 
Luminex xMAP Bead-based 100 
Meso Scale Discovery MULTI-ARRAY 
and MULTI-SPOT 
Planar array 100 
Ray Biotech Quantibody Planar array 40 
R&D Systems Proteome Profiler Planar array 16 
Quansys Q-Plex Planar array 16 
BD Biosciences Cytometric Bead Array Bead-based 30 
Table 5.1. Commercially available multiplex platforms. Numerous companies have entered 
the multiplex ELISA technology space. Planar arrays have capture antibodies fixed to the surface 
of a 96-well plate, glass slide, or membrane, while bead-based assays have capture antibodies 
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Conclusions and Future Directions 
The drug development process has become increasingly inefficient as biotech and 
pharmaceutical companies have invested billions of dollars in their drug development pipelines, 
only to see an overwhelming majority of drug compounds fail in clinical trials. There are many 
contributing factors to this trend that include biological and physiological complexities of the 
diseases being targeted, strategic business portfolio management to pursue high risk and 
potential high reward projects, and difficult regulatory requirements that make it challenging to 
successfully navigate clinical trials, to name a few. 
New technological advances should enable these companies to become more successful; 
for example, increased knowledge of the human genome and microbiome, better biostatistical 
analysis and epidemiological understanding of diseases, and the implementation of next-
generation technologies that increase the amount and quality of data generated and better model 
in vivo pathophysiology will improve all aspects of drug development from initial compound 
screening to clinical trials. Unfortunately, to date many of these so-called enabling technologies 
have yet to cause paradigm shifts and/or drastic changes in the way biotech and pharmaceutical 
companies conduct drug development. The disconnect in excitement surrounding these 
technologies and their actual impact can be attributed to difficulties in adoptability, 
reproducibility, manufacturability, and scalability, to name a few. For example, cutting edge 
research is often performed in academic settings or labs heavily geared toward basic science. 
116 
 
While many of these labs do make significant contributions to the understanding of diseases and 
technological capabilities, there has been a lack of translation into commercially viable entities. 
Until this gap is closed, potentially fruitful technologies will continue to flounder.  
ATPS assays may be able to overcome the limitations associated with many of these 
previously-developed technologies. For example, ATPSs are highly biocompatible and can be 
implemented with tissue, cells (including plant, bacterial, and mammalian), proteins, and nucleic 
acids, thereby enabling the development of assays to test the biological material of interest. 
Furthermore, these systems are very easy to adopt as they only require the formulation of 
solutions and dispensing with pipettors or liquid handlers. Finally, due to the patternability of 
ATPSs, it is easy to achieve high-throughput arrays for various types of tests. 
Included in this dissertation are four concrete examples of ways in which ATPSs were 
used in the early development of next-generation in vitro assays. First, localized and multiplexed 
immunocytochemistry was used to show that antibodies partition to DEX in a PEG/DEX ATPS 
and that this approach can be used to stain for multiple biomarkers in parallel from a single cell 
monolayer; furthermore, this technique enables faster antibody binding and higher signal 
intensity (likely due to greater antibody binding) than traditional staining formats. An ATPS of 
5% polyethylene glycol (PEG) and 12.8% dextran (DEX) was then determined to be the optimal 
system with which to perform cell monoculture patterning for high-throughput screening 
analysis of cell migration and to perform co-culture patterning to achieve more physiologically 
relevant cell behavior that can be used as a toxicological and/or functional screening assay. An 
ATPS was further used to create an assay that localizes trypsin to achieve reproducible and high-
throughput in vitro wounding on transwell inserts (which to this point has not been possible). 
Finally, an ATPS-enzyme-linked immunosorbent assay (ELISA) was developed to pattern 
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detection antibodies and quantify 4 biomarkers of graft-versus-host-disease without antibody 
cross-reactivity and with greater sensitivity compared to traditional ELISA. These proofs-of-
concept demonstrate ways in which ATPS assays can be implemented at various points in the 
drug development process to improve the likelihood of generating an FDA-approved compound. 
Future work will still be needed to validate and translate these technologies to the point 
where they can be implemented on a large scale. Multiplexed immunocytochemistry will need to 
be expanded upon to achieve staining and multiplexed protein detection of histological samples; 
although the process will be essentially the same in this format, it will be crucial to demonstrate 
this capability to make it amenable to eventual users. Furthermore, in terms of using the 
technology for diagnosis and/or biomarker discovery, it will be necessary to develop a scoring 
system in which researchers and/or clinicians can assign grades to samples based on the amount 
and/or intensity of staining. To this end, it would also be useful to develop image analysis 
software or other methodology that could quantify protein expression levels based on staining 
intensity.  
With regards to multiplex cell patterning, it will be important to demonstrate cell 
patterning in a 96-well plate as opposed to large dishes to show its utility in a format more likely 
to be used in screening. Furthermore, although we qualitatively demonstrated improved 
hepatocyte function in a patterned co-culture format, it will be important to extend co-culture 
patterning to primary cells and with quantitative readouts. These patterned primary cell co-
cultures could be very useful in drug screening; for example, by using patterned primary 
hepatocytes and support cells it could be possible to develop a platform that better predicts off-
target hepatic toxicity in vitro at early stages. This would enable scientists to make more 
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informed decisions about whether or not to pursue a potential compound and potentially save 
billions of dollars in downstream optimization and clinical trials expenses. 
The ATPS in vitro wound assay will also require further development that is similar to 
the co-culture patterning technique. We demonstrated the utility of this assay with A549 cells 
cultured on transwell inserts; however, it will be more instructive to demonstrate this assay with 
primary cell lines that undergo more pronounced differentiation when maintained at ALI. 
Furthermore, it would be interesting to combine this assay with compounds that interact with 
mucins and other biological molecules present with cells cultured at ALI to monitor their effects 
on wound closure (which could not be done with cells in submersion culture). It would also be 
interesting to modify the wounding technique so that instead of locally delivering trypsin to 
achieve a denuded cell area, small particulate and/or biological matter were delivered locally to 
model inspired particles depositing on small areas of the lung to monitor subsequent cell 
signaling and repair that occurs in vivo. Finally, it would be interesting to expand the application 
of this technology to other non-traditional cell culture settings such as soft polyacrylamide, 
which better models tissue stiffness of organs such as the lungs. 
 Lastly, the ATPS-ELISA technique was significantly validated for its use with patient 
plasma in a completely hydrated format. Although this approach is easy in the regard that it only 
requires pipetting and does not require any extra complicated instrumentation, it still requires 
user skill and knowledge to be able to reproducibly perform the assay. Therefore, to be able to 
use ATPS-ELISA on a large scale, it will be necessary to modify the assay so as to minimize 
user handling and potential for error due to pipetting mistakes. In this regard, creating a plate 
with pre-dehydrated (or lyophilized) and spotted capture and detection antibody pairs could be a 
viable solution. In this format, the only steps the end user would have to perform would be to 
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enrich their sample of interest with PEG and add the PEG-enriched solution to wells, thereby 
making it much easier to adopt into lab settings. Furthermore, we have only validated the 
technology for a 4-plex panel of biomarkers from patient plasma. The capability of this assay 
should also be investigated for higher degrees of multiplex detection and with other sample 
matrices such as urine. 
The ATPS assays described here are exciting first steps in their development as next-
generation technologies that can increase throughput and provide better physiological relevance 
compared with other in vitro assays. Further technological advancements and biological proofs-
of-concept will enable them to be implemented as useful screening tools in the drug development 
process. 
